Published in final edited form as:

J Med Chem. 1999 May 06; 42(9): 1625–1638. doi:10.1021/jm980657j.

Structure-Activity Relationships of Bisphosphate Nucleotide Derivatives as P2Y₁ Receptor Antagonists and Partial Agonists

Erathodiyil Nandan[†], Emidio Camaioni[†], Soo-Yeon Jang[†], Yong-Chul Kim[†], Gloria Cristalli^{||}, Piet Herdewijn[⊥], Ill John A. Secrist[§], Kamal N. Tiwari[§], Arvind Mohanram[‡], T. Kendall Harden[‡], José L. Boyer[‡], and Kenneth A. Jacobson^{*,†}

[†] NIH

[‡] University of North Carolina, School of Medicine

[§] Southern Research Institute

^{||} Università di Camerino

[⊥] Katholieke Universiteit Leuven

Abstract

The P2Y₁ receptor is present in the heart, in skeletal and various smooth muscles, and in platelets, where its activation is linked to aggregation. Adenosine 3',5'- and 2',5'-bisphosphates have been identified as selective antagonists at the P2Y₁ receptor (Boyer et al. *Mol. Pharmacol.* **1996**, *50*, 1323–1329) and have been modified structurally to increase receptor affinity (Camaioni et al. *J. Med. Chem.* **1998**, *41*, 183–190). We have extended the structure-activity relationships to a new series of deoxyadenosine bisphosphates with substitutions in the adenine base, ribose moiety, and phosphate groups. The activity of each analogue at P2Y₁ receptors was determined by measuring its capacity to stimulate phospholipase C in turkey erythrocyte membranes (agonist effect) and to inhibit phospholipase C stimulation elicited by 10 nM 2-(methylthio)adenosine 5'-diphosphate (antagonist effect). 2'-Deoxyadenosine bisphosphate analogues containing halo, amino, and thioether groups at the 2-position of the adenine ring were more potent P2Y₁ receptor antagonists than analogues containing various heteroatom substitutions at the 8-position. An *N*⁶-methyl-2-chloro analogue, **6**, was a full antagonist and displayed an IC₅₀ of 206 nM. Similarly, *N*⁶-methyl-2-alkylthio derivatives **10**, **14**, and **15** were nearly full antagonists of IC₅₀ < 0.5 μM. On the ribose moiety, 2'-hydroxy, 4'-thio, carbocyclic, and six-membered anhydrohexitol ring modifications have been prepared and resulted in enhanced agonist properties. The 1,5-anhydrohexitol analogue **36** was a pure agonist with an EC₅₀ of 3 μM, i.e., similar in potency to ATP. 5'-Phosphate groups have been modified in the form of triphosphate, methyl phosphate, and cyclic 3',5'-diphosphate derivatives. The carbocyclic analogue had enhanced agonist efficacy, and

*Correspondence to: Dr. Kenneth A. Jacobson, Chief, Molecular Recognition Section, Bldg 8A, Rm B1A-19, NIH, NIDDK, LBC, Bethesda, MD 20892-0810. Tel: (301) 496-9024. Fax: (301) 480-8422, kajacobs@helix.nih.gov.
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, Department of Pharmacology, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27599-7365, Organic Chemistry Research Department, Southern Research Institute, P.O. Box 55305, Birmingham, Alabama 35255-5305, Dipartimento di Scienze Chimiche, Università di Camerino, 62032 Camerino, Italy, and Laboratory of Pharmaceutical Chemistry, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

the 5'-*O*-phosphorylmethyl modification was tolerated, suggesting that deviations from the nucleotide structure may result in improved utility as pharmacological probes. The *N*⁶-methoxy modification eliminated receptor affinity. Pyrimidine nucleoside 3',5'-bisphosphate derivatives were inactive as agonists or antagonists at P2Y receptor subtypes.

Introduction

Extracellular adenine and uracil nucleotides act in cell signaling through two families of plasma membrane receptors: the G protein-coupled receptors and the ligand-gated cation channels, termed P2Y and P2X, respectively.^{1,2} Molecular biological techniques have led to the discovery of new nucleotide receptor subtypes. The P2Y1 receptor for purine nucleotides from chick brain was the first subtype of the P2Y receptor to be cloned.³ The human P2Y1 subtype^{4,5} has also been cloned, and the gene for the human P2Y1 receptors is localized to chromosome 3.⁶ Four other distinct, cloned P2Y subtypes are P2Y2 (formerly called P2U), P2Y4, P2Y6, at which uracil nucleotides are particularly active, and P2Y11, which is activated by ATP.^{7,8} Among the three uracil nucleotide-responsive P2Y receptors, the P2Y2 is activated equally by ATP and UTP. While the P2Y₄ subtype is mainly activated by UTP, the P2Y₆ is activated by UDP. Recently it was found that uracil nucleotides are released from cells in a manner similar to adenine nucleotides, and this has implications for P2Y receptor activation.⁹

Agonist binding at P2Y1 receptors results in activation of phospholipase C (PLC), which generates inositol phosphates and diacylglycerol from phosphatidylinositol 4,5-bisphosphate.¹⁰ The P2Y1 receptor is present in the heart, in skeletal and various smooth muscles, and in the brain. A P2Y1 receptor in platelets is involved in ADP-promoted aggregation.^{11,12} Thus, a selective P2Y1 receptor antagonist may have potential as an antithrombotic agent. A selective P2Y1 receptor agonist also has potential as an antihypertensive and possibly antidiabetic agent.^{13,14}

Few potent and selective P2 receptor antagonists are known.^{15–18} However, adenosine 3',5'- and 2',5'-bisphosphates were recently shown to be selective inhibitors of P2Y1 receptors,¹⁹ and a novel series of bisphosphate adenosine analogues has been synthesized as potent and selective P2Y1 receptor antagonists.²⁰ Among them, N⁶-methyl-2'-deoxyadenosine 3',5'-bisphosphate (MRS 2179, 2; Table 1) was synthesized and is a competitive antagonist at the turkey P2Y1 receptor with a KB value of 102 nM.²¹ MRS 2179 was inactive at P2Y2, P2Y4, and P2Y6 subtypes, at the adenylyl cyclase-linked P2Y receptor in C6 glioma cells (J. Boyer, personal communication),²² and at a recently cloned, novel avian P2Y receptor that inhibits adenylyl cyclase.²³ The antagonist MRS 2179, although competitive and selective, does not have sufficiently high affinity for use as a radioligand. Thus, further structural modifications directed at increasing affinity as well as biological stability have been carried out in the present study.

Results

Chemical Synthesis.

The recent discovery of *N*⁶-methyl-2'-deoxyadenosine 3',5'-bisphosphate (**2**; Table 1) as a competitive antagonist at P2Y₁ receptors^{20,21} led us to explore further structural modifications of this molecule in order to increase P2Y₁ receptor affinity and selectivity. We have prepared 2'-deoxyadenosine bisphosphate analogues containing halo, amino, and thioether groups at the 2-position of the adenine ring or various heteroatom substitutions at the 8-position (Table 1). Carbocyclic, 4'-thio, and six-membered ring modifications have been prepared on the ribose moiety. 5'-Phosphate groups have been modified in the form of triphosphate, methylphosphonate, and cyclic 3',5'-diphosphate derivatives (Figure 1). Pyrimidine 3',5'-bisphosphate analogues also were included (Figure 1), since other subtypes of P2Y receptors are known to recognize uridine 5'-di- and triphosphates.^{1,7}

Some of the nucleosides utilized for phosphorylation were obtained commercially, leading to compounds **3**, **5**, **17b**, and **32-35**. Other nucleosides were synthesized as reported, leading to compounds **4**, **18**, **19**, **23**, **24**, **30**, **31**, and **36**,²⁴⁻²⁸ or alternatively were synthesized as shown in Schemes 1-6.

2-Halo groups were introduced in the structure of the lead compound **2** resulting in compounds **6** (Scheme 1) and **7** (Scheme 2). Commercially available cladribine, **37** (2-chloro-2'-deoxyadenosine), was acetylated²⁹ to give the diacetate **38** which upon diazotization-iodination followed by treatment with methylamine resulted in the *N*⁶-methyl derivative **39** in 42% yield. Compound **39** was phosphorylated to give the 2-chloro analogue **6**. The 2-iodo analogue **7** was prepared in seven steps (Scheme 2). 2'-Deoxyguanosine, **45**, was acetylated to the diacetate **46** in 75% yield using acetic anhydride and pyridine, as reported in the literature.²⁹ Chlorination of **46** with POCl₃ in the presence of *N,N*-dimethylaniline and tetraethylammonium chloride in acetonitrile at 100 °C afforded the 6-chloro derivative **47**, which on treatment with methylamine resulted in 2-amino-*N*⁶-methyladenosine, **48**, in 55% yield. Acetylation²⁹ of **48** followed by diazotization-iodination and hydrolysis furnished 2-iodo-*N*⁶-methyladenosine, **50**, in 48% yield (Scheme 2).

2'-Deoxyadenosine nucleotides modified at the 2-position with thioether (**9-16**) and amino (**17**) groups were also synthesized. Cladribine, **37**, on nucleophilic displacement with the potassium salt of methyl-, ethyl-, or propylthiol afforded the corresponding 2-thio derivatives **51-53**, in 70-80% yield (Scheme 3), leading to phosphorylated 2-alkylthio analogues **9**, **11**, and **13**. To obtain the corresponding *N*⁶-methyl derivatives, 2-chloro-*N*⁶-methyl-2'-deoxyadenosine (**39**; Scheme 1) was converted to various 2-thioethers by displacement of chlorine at the 2-position with the corresponding alkanethiol potassium salts in 70-80% yield, leading to compounds **10**, **12**, and **14-16**.

The synthetic approach for the modification at the 8-position utilized commercially available 2'-deoxyadenosine, **54**, as the starting compound (Scheme 4). Bromination of **54** using NBS yielded the 8-bromo derivative, **55**, in 40% yield. Displacement of bromine on **53** with various nucleophiles, sodium methoxide, methylamine, or sodium thiomethoxide furnished the corresponding substituted products **56-58** in ~70-90% yield. Phosphorylation of **56-58**

and 8-methyl- or 8-vinyl-substituted 2'-deoxyadenosine derivatives³⁰ using the general phosphorylation conditions resulted in the corresponding bisphosphates **18-22** in low to moderate yields.

Compound **8**, i.e., the methoxy analogue of **2**, was prepared. The nucleoside precursor to be phosphorylated, **59**, was synthesized by reaction of methoxyamine and 6-chloro-2'-deoxypurine riboside using the general method previously described.²⁰

We prepared the bisphosphates of 1,5-anhydro-2-(adenin-9-yl)-2,3-dideoxy-D-*arabino*-hexitol,²⁵ 4'-thioadenosine,^{26,31} **23**, and carbocyclic³² analogues, **24** and **25**, of 2'-deoxyadenosine 3',5'-bisphosphate (Table 1). Although difficulties in phosphorylation of 4'-thiopyrimidines were previously reported,³⁷ we have isolated the bisphosphate derivative of 4'-thioadenosine by HPLC of a mixture in low yield. The optimal reaction conditions were a brief reaction time (20 min) at 0 °C. Carbocyclic 2-amino-6-chloropurine 2'-deoxyriboside²⁷ was phosphorylated to provide **24**. For inclusion of 2-position substitution, carbocyclic 2-amino-6-chloropurine 2'-deoxyriboside was treated with methylamine and phosphorylated (Scheme 5). 2'-Deoxy-4'-thioadenosine, **62**, was also oxidized to the corresponding sulfoxide **63**, which upon phosphorylation provided only the 5'-monophosphate **26** (Scheme 5).

The effect of various substitutions and hence various charges on the phosphates also was examined. An *O*-phosphonylmethyl group was introduced selectively at the 5'-position followed by phosphorylation at the 3' position (Scheme 6) resulting in compound **27**. Reaction of 2'-deoxyadenosine, **54**, with diethyl tosyl methylphosphonate in the presence of potassium *tert*-butoxide in DMF for 3 days yielded the 5'-diethyl phosphonate of 2'-deoxyadenosine **64** in 32% yield, which was phosphorylated by a general procedure to provide compound **27**. Alternatively, phosphorylation of **54** using the general procedure with methyl dichlorophosphate yielded the corresponding bis(methyl phosphate) **28** in good yield. Attempted phosphorylation of the 3',5'-bisphosphate **2** to prepare corresponding 5'-di- and triphosphates resulted instead in isolation of 3',5'-cyclic di- and tetraphosphates **29a** and **29b** (Scheme 7). The structures of the 3',5'-cyclic phosphate derivatives were assigned by 2D phosphorus and proton-phosphorus decoupling NMR analysis.

Biological Activity.

The deoxyadenosine bisphosphate nucleotide analogues prepared in the present study were tested separately for agonist and antagonist activity in the PLC assay at the P2Y₁ receptor in turkey erythrocyte membranes,^{21,39} and the results are reported in Table 2. Concentration-response curves were obtained for each compound alone and in combination with 2-(methylthio)adenosine 5'-diphosphate 2-MeSADP, which itself resulted in a marked and concentrationdependent activation of the turkey erythrocyte phospholipase C.²¹ 2-MeSADP was used at a concentration of 10 nM (approximately) EC₅₀). The activities of all the newly synthesized analogues were compared to that of **2**, which we previously identified as the highest potency P2Y₁ receptor antagonist thus far identified.^{20,21} Concentration-response curves for representative compounds are shown in Figure 2.

The presence of the 2'-hydroxyl group in the arabinose derivative **3** compared to the corresponding 2'-deoxy compound **1** resulted in a 3-fold loss of antagonist potency and an increase in the agonist potency and efficacy. The 1-deaza modification in **4** was tolerated at P2Y₁ receptors, resulting in a 3-fold loss of antagonist potency versus the corresponding aza analogue **2**. The combination of 2-halo and N⁶-methyl groups resulted in higher antagonist potency for the chloro derivative **6** (IC₅₀ 0.20 μM, Figure 2) and a lower potency for the iodo derivative **7** in comparison with **2**. Both **6** and **7** were nearly pure antagonists. The 6-(methoxyamino)purine analogue **8** was nearly inactive at P2Y₁ receptors, which is consistent with the previously observed critical requirement for a 6-amino or small alkylamino group.

Substitution at the adenine 2-position was generally well-tolerated at P2Y₁ receptors and was compatible with the antagonist potency-enhancing effects of an N⁶-methyl group. For example, the N⁶-methyl-2-methylthio analogue **10** was nearly a full antagonist and equipotent to the corresponding 2-H analogue **2**. Compound **10** was 5-fold more potent as an antagonist than the corresponding 6-NH₂ analogue **9** (Figure 2), which also displayed agonist activity. The 2-ethylthio substitution curiously resulted in ~3-fold lower potency than 2-methylthio, either as an agonist (in the case of the 6-aminopurine, **11**) or as an antagonist (with N⁶-methyl substitution, **12**). The N⁶-methyl-2-propylthio analogue **14** was an antagonist, while the corresponding 6-NH₂ analogue **13** was a mixed agonist/antagonist of equal proportions. The 2-allylthio and 2-*n*-hexylthio analogues containing the N⁶-methyl substitution, **15** and **16**, respectively, were full antagonists. The allylthio and *n*-propylthio analogues were equipotent (0.4–0.5 μM IC₅₀), while the *n*-hexylthio analogue was 7-fold less potent as an antagonist. Thus, as for P2Y₁ receptor agonists,^{33,34} the 2-position can accommodate steric bulk without substantial loss of potency as a P2Y₁ receptor antagonist. Substitutions at the 2-position other than thioethers were also studied. The 2-amino-N⁶-methyl analogue **17a** was an antagonist of moderate potency. The corresponding 6-hydroxyl (deoxyguanosine) analogue **17b** was an 8-fold weaker antagonist than **17a**.

8-Position substitution in the methyl, vinyl, methoxy, methylthio, and methylamino analogues **18–22** resulted in only weak P2Y₁ receptor antagonist properties, similar to the activity previously reported for the 8-bromo analogue. Within this group, carbon substituents, such as the 8-vinyl group, in **19**, were best tolerated at P2Y₁ receptors, while the 8-methyloxy substituent, in **20**, resulted in a complete loss of activity.

Ribose ring substitutions tended to enhance the agonist properties of the derivatives. The 4'-thio analogue **23** and the carbocyclic analogue **24** were mixed agonist/antagonists, with the 4'-thio being more efficacious in receptor activation. The N⁶-methyl-2-amino carbocyclic analogue **25** was also a mixed agonist/antagonist but was 2-fold less potent than **24** as an antagonist. Compound **26**, a sulfoxide 5-monophosphate, was inactive at P2Y₁ receptors.

Phosphate group modifications were made. The 5' phosphonate analogue **27** was a mixed agonist/antagonist. While producing a 78% maximal inhibition, **27** had antagonist potency that was only 3.5-fold lower than for the corresponding 5'-phosphate **1**. The dimethyl phosphate **28** and the 3',5'-cyclic diphosphate **29a** were essentially inactive at P2Y₁ receptors. The 3',5'-cyclic tetraphosphate **29b** displayed potent antagonist activity; however the possibility of hydrolysis of the unusual cyclic structure during the assay was not

explored. The effect of lengthening the 5'-substituent from a monophosphate to a triphosphate was examined in 3'-deoxy-3'-azidoxylose derivatives, compounds **30** and **31**. The triphosphate was a weak agonist, while the monophosphate was nearly inactive, suggesting that the triphosphate group may tend to enhance agonist potency versus the 5'-monophosphate, as was observed for nucleotides phosphorylated solely at the 5'-position.³³

Introduction of a variety of pyrimidine bases in compounds **32-35** completely abolished both agonist and antagonist activity at P2Y₁ receptors. In addition, the 2'-deoxyuridine derivative **32** at 100 μ M was shown to be inactive as either an agonist or antagonist at P2Y₂, P2Y₄, or P2Y₆ receptors (all of which are activated by uracil nucleotides) and at the C6 glioma P2 receptor²² linked to inhibition of adenylyl cyclase.

The ribose was also replaced with a six-membered ring in which the glycosidic bond was absent. Thus, the enlargement of the ribose ring in the anhydrohexitoladenine²⁵ derivative **36** resulted in a pure P2Y₁ receptor agonist activity, with an EC₅₀ of 3 μ M (Figure 2).

Discussion

The aim of the present study was to synthesize novel analogues and isosteres of **2** in order to increase the affinity and/or alter the efficacy of these nucleotides as antagonists, mixed agonists, or pure agonists at turkey P2Y₁ receptors. The major conclusions are that 2-position substituents are compatible with the 2'-deoxy modification and in fact may enhance affinity, as in the 2-chloro analogue **6**, and that substantial modification of the ribose moiety is possible. However, the agonist component of the biological activity of the bisphosphate analogues tends to increase upon 2-alkylthio substitution. This was particularly pronounced in the absence of the N⁶-methyl group. The effect of length of 2-alkylthio ethers on antagonist activity does not strictly follow the trend previously observed for potency of 5'-monophosphate agonists, e.g., 2-hexylthio > 2-methylthio. In the present series the most potent antagonists among the 2-thioethers were the *S*-methyl, propyl, and allyl analogues **10**, **14**, and **15**, respectively, which also contained an N⁶-methyl group. In the 2-alkylthioether series, the presence of the N⁶-methyl group greatly decreased agonist efficacy. Amino substitution at the 2-position also was found to be tolerated in P2Y₁ receptor antagonists.

Among intended isosteres **2**, we observed that the carbocyclic analogue **24** was active as a mixed agonist/antagonist at P2Y₁ receptors. The carbocyclic modification is expected to increase the in vivo stability of the compounds since these are *N*-cycloalkyl analogues, and the equivalent of deglycosylation is not expected to readily occur. The carbocyclic modification also may increase the selectivity of the compounds for P2 receptors, since these are structurally distinct from natural nucleotides.

The balance of agonist versus antagonist properties was highly dependent on ribose modifications, particularly at the 2'- and 4'-positions. Substitution at the ribose 2'-position generally appeared to increase the degree of agonism observed, as is evident from the present and previous²⁰ sets of analogues (Figure 3). The presence of a 2'-hydroxyl, in either configuration, or a 2'-methoxy group increased the agonist efficacy. Perhaps the most unexpected result was that an expansion of the ribose ring in the 1,5-anhydrohexitol-adenine

derivative, **36**, results in pure agonism at the turkey P2Y₁ receptor. As for the five-membered carbocyclic analogue **24**, compound **36** would be resistant to deglycosylation by the usual mechanisms.

In general, for pharmacological studies of receptor subtypes, highly selective antagonists are preferable. However, for some therapeutic applications partial agonists may provide low intrinsic activities that might avoid side effects.³⁵ For example, pindolol is such a partial agonist at β_1 -adrenergic receptors and displays diminished bradycardiac side effects.³⁶ Thus, the partial agonists in this series of nucleotide derivatives may potentially be therapeutically useful in modulating the activity of P2Y₁ receptors. The effects of partial P2Y₁ receptor agonists on platelet aggregation or on insulin release have not yet been explored.

A preliminary report³⁷ indicates that **2** is a relatively potent antagonist at rat P2X₁ receptors with an IC₅₀ value of 1.2 μ M, as determined in a study of ATP-induced ion flux in *Xenopus* oocytes transfected with the recombinant rat P2X₁ receptor. In similar experiments using rat P2X₂ and P2X₄ receptors, no antagonist activity was observed, and at rat P2X₃ receptors only weak antagonism was observed. The finding of affinity of **2**, an N⁶-methyl derivative, at P2X₁ receptors is in contrast with findings previously observed for adenosine 5'-triphosphate derivatives as agonists,^{33, 34} in which the presence of the N⁶-methyl group precluded activity at guinea pig vas deferens or urinary bladder P2X receptors. Thus, **2** is a selective antagonist for P2Y₁ receptors within the family of metabotropic P2 receptors and a selective antagonist for P2X₁ receptors within the family of ionotropic P2 receptors. The effects on activity at P2X receptors of the structural modifications of **2** reported in the present study have yet to be determined.

In platelets, three subtypes¹¹ of P2 receptors are present: P2X₁, P2Y₁, and a yet uncloned P2_T receptor, which inhibits adenylate cyclase. A P2Y₁ receptor antagonist may prove to inhibit platelet aggregation,¹² as do adenosine 5'-triphosphate analogues. There has been some discussion of whether ATP acts as a pure antagonist or as a partial agonist in platelets. It has been proposed that ATP itself has lower efficacy than ADP at a platelet P2Y receptor, and that may be why it apparently antagonizes the effects of ADP.¹⁵ Furthermore, in platelets, the presence of P2X₁ antagonist properties, as has been demonstrated for **2**,³⁷ may increase the potential utility as antiaggregatory agents through action at two receptors having the same net pharmacological effect, i.e. platelet aggregation. Other members of the present series may also prove to be dual antagonists.

We have used mutagenesis and molecular modeling of human P2Y₁ receptors to define a hypothetical nucleotide binding site, defined by TM3, TM6, and TM7 domains, for both the agonist 2-MeSADP and the antagonist **2**. In the present study we have determined structural features which dramatically influence the degree of efficacy of the compound, such that nearly pure agonists and pure antagonists are present among closely related derivatives.

The pyrimidine nucleotide, 2'-deoxyuridine 3',5'-bisphosphate, **32**, was found to be inactive at subtypes of P2Y receptors known to be activated by uracil nucleotides, e.g., P2Y₂, P2Y₄, and P2Y₆. At the P2Y₂ receptor this was not surprising, since in the SAR of nucleotide agonists at this subtype a 5'-triphosphate group is required for activation.

However, even P2Y₆ receptors, which are activated by UDP, would not accept as ligand the 2'-deoxy-3',5'-bisphosphate analogue **32**. Thus, the search for effective antagonists at these subtypes continues.

In conclusion, the present study has identified new pharmacological probes of P2Y₁ receptors. The SAR of **2** indicates that 2-position substitution is favorable for affinity at P2Y₁ receptors, and nearly pure antagonism is maintained provided that the N⁶-methyl group is present. An N⁶-methyl-2-chloro analogue **6** was a full antagonist and displayed an IC₅₀ of 206 nM. Similarly, N⁶-methyl-2-alkylthio derivatives **10**, **14**, and **15** were nearly full antagonists of IC₅₀ < 0.5 μM. Thus, the affinity of 2-substituted N⁶-methyl analogues decreases in the order: Cl > H, SCH₃ > S-propyl, S-allyl > NH₂, S(CH₂)₅CH₃. The 2-(propylthio)-6-aminopurine analogue **13** is the most potent mixed agonist/antagonist, in which the two components are roughly equal. Among nucleotides with mixed agonist and antagonist properties, but in which the antagonist component predominates, compounds **5** and **9**, 2-chloro- and 2-(methylthio)-6-aminopurine analogues,²⁰ respectively, are the most potent. The 1,5-anhydrohexitol-adenine derivative **36** is a pure agonist of potency similar to ATP.³³

Experimental Section

Chemical Synthesis.

Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. Louis, MO) and Aldrich (St. Louis, MO). 6-Chloro-2'-deoxypurine riboside was obtained from Sigma. MRS 2179 was synthesized in our laboratory as described.²⁰ Several 2'-deoxynucleosides, including 1-deaza-2'-deoxyadenosine,²⁴ anhydrohexitol-adenine nucleoside,²⁵ 2'-deoxy-4'-thioadenosine,²⁶ 2'-deoxyaristeromycin,²⁷ 8-alkyl-2'-deoxyadenosine,³⁰ and 3'-deoxy-3'-azidoxylose,²⁸ were synthesized as reported.

¹H NMR spectra were obtained with a Varian Gemini-300 spectrometer using D₂O as a solvent. ³¹P NMR spectra were recorded at room temperature by use of a Varian XL-300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was used as an external standard.

Purity of compounds was checked by a Hewlett-Packard 1090 HPLC apparatus using SMT OD-5-60 RP-C18 250 × 4.6 mm; Separation Methods Technologies, Inc., Newark, DE) as an analytical column in two solvent systems. The flow rate was 1 mL/min, with a typical pressure of 100 bar. System A: linear gradient solvent system, 0.1 M TEAA/CH₃CN from 95/5 to 40/60 in 20 min. System B: linear gradient solvent system, 5 mM TBAP/CH₃CN from 80/20 to 40/60 in 20 min. Peaks were detected by UV absorption using a diode array detector. All derivatives showed more than 95% purity in HPLC system.

Low-resolution CI-NH₃ (chemical ionization) mass spectra were carried out with a Finnigan 4600 mass spectrometer and high-resolution EI (electron impact) mass spectra with a VG7070F mass spectrometry at 6 kV. High-resolution FAB (fast atom bombardment) mass spectrometry was performed with a JEOL SX102 spectrometer using 6-kV Xe atoms following desorption from a glycerol matrix.

Purification of most of the nucleotide analogues was carried out on DEAE-A25 Sephadex columns as described below. However, compounds **17a**, **18**, and **22** (system A) and compounds **26** and **36** (system B followed by Sephadex column) required HPLC purification (semipreparative C18 column) of the reaction mixtures.

General Procedure of Phosphorylation.

Nucleoside (0.1 mmol) and Proton Sponge (¹⁰⁷ mg, 0.5 mmol) were dried for several hours in high vacuum at room temperature and then suspended in 2 mL of trimethyl phosphate. Phosphorus oxychloride (³⁷ μ L, 0.4 mmol) was added, and the mixture was stirred for 1 h at 0 °C. The reaction was monitored by analytical HPLC (eluting with gradient from buffer, CH₃CN) 95:5 to 40:60; buffer, 0.1 M triethylammonium acetate (TEAA); elution time, 20 min; flow rate, 1 mL/min; column, SMT OD-5–60 RP-C18; detector, UV, $E_{\text{max}} \sim 260\text{--}300$ nm). The reaction was quenched by adding 2 mL of triethylammonium bicarbonate buffer and 3 mL of water. The mixture was subsequently frozen and lyophilized. Purification was performed on an ion-exchange column packed with Sephadex-DEAE A-25 resin, linear gradient 0.01–0.5 M) of 0.5 M ammonium bicarbonate was applied as the mobile phase, and UV and HPLC were used to monitor the elution. All nucleotides were collected, frozen, and lyophilized as the ammonium salts. All synthesized compounds gave correct molecular masses and showed more than 95% purity (high-resolution FAB, purity, and HPLC retention times are reported in Table 3).

Adenine Arabinofuranoside 3',5'-Bis(diammonium phosphate) (3).

Starting from 40 mg (0.15 mmol) of adenine arabinofuranoside and following the general procedure, using an additional 2 mL of acetonitrile to dissolve starting material, we obtained 11.2 mg (0.023 mmol, 15% yield) of **3**: ¹H NMR (D₂O) δ 4.09 (2H, m, CH₂-5'), 4.33 (1H, bs, H-4'), 4.56 (1H, m, H-2'), 4.65 (1H, m, H-3'), 6.43 (1H, d, $J = 3.9$ Hz, H-1'), 8.18 (1H, s, H-2), 8.50 (1H, s, H-8); ³¹P NMR (D₂O) δ 3.49 (s, 1-P), 3.70 (d, $J = 6.0$ Hz, 1-P).

2'-Deoxy-1-deaza-N⁶-methyladenosine 3',5'-Bis(diammonium phosphate) (4).

Starting from 14 mg (0.053 mmol) of 2'-deoxy-1-deaza-N⁶-methyladenosine and following the general procedure, we obtained 4.2 mg (0.009 mmol, 17% yield) of **4**: ¹H NMR (D₂O) δ 2.76 (2H, m, CH₂-2'), 3.06 (3H, s, NHCH₃), 4.11 (2H, m, CH₂-5'), 4.49 (1H, bs, H-4'), 4.97 (1H, m, H-3'), 6.45 (1H, t, $J = 6.8$ Hz, H-1'), 6.59 (1H, d, $J = 6.8$ Hz, H-1'), 8.02 (1H, d, $J = 6.8$ Hz, H-2), 8.32 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.56 (d, $J = 16.6$ Hz, 3'-P), 1.43 (bs, 5'-P).

2-Chloro-2'-deoxy-N⁶-methyladenosine 3',5'-Bis(diammonium phosphate) (6).

Starting from 25 mg (0.083 mmol) of 2-chloro-2'-deoxy-N⁶-methyladenosine, **39**, and following the general procedure, we obtained 7.5 mg (0.014 mmol, 17% yield) of **6**: ¹H NMR (D₂O) δ 2.76 (2H, m, CH₂-2'), 2.95 (3H, s, NHCH₃), 4.06 (2H, m, CH₂-5'), 4.43 (1H, bs, H-4'), 4.96 (1H, m, H-3'), 6.32 (1H, t, $J = 6.9$ Hz, H-1'), 8.31 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.06 (d, $J = 9.0$ Hz, 3'-P), 0.73 (bs, 5'-P).

2'-Deoxy-2-iodo-*N*⁶-methyladenosine 3',5'-Bis(diammonium phosphate) (7).

Starting from 28 mg (0.072 mmol) of 2'-deoxy-2-iodo-*N*⁶-methyladenosine, **50**, and following the general procedure, we obtained 6.6 mg (0.012 mmol, 17% yield) of **7**: ¹H NMR (D₂O) δ 2.31 (1H, m, CH₂-2'), 2.97 (1H, m, CH₂-2'), 3.13 (3H, s, NHCH₃), 4.11 (2H, m, CH₂-5'), 4.46 (1H, m, H-4'), 5.06 (1H, m, H-3'), 6.65 (1H, t, *J* = 5.9 Hz, H-1'), 8.65 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.56 (bs, 5'-P), -0.19 (bs, 3'-P).

2'-Deoxy-*N*⁶-methoxyadenosine 3',5'-Bis(diammonium phosphate) (8).

Starting from 12 mg (0.043 mmol) of 2'-deoxy-*N*⁶-methoxyadenosine, **59**, and following the general procedure, we obtained 5.1 mg (0.010 mmol, 23% yield) of **8**: ¹H NMR (D₂O) δ 2.75 (2H, m, CH₂-2'), 3.84 (3H, s, OCH₃), 4.04 (2H, m, CH₂-5'), 4.43 (1H, bs, H-4'), 4.97 (1H, m, H-3'), 6.45 (1H, t, *J* = 6.9 Hz, H-1'), 7.95 (1H, s, H-2), 8.30 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.60 (d, *J* = 7.5 Hz, 3'-P), 1.13 (bs, 5'-P).

2'-Deoxy-2-(methylthio)-*N*⁶-methyladenosine 3',5'-Bis(diammonium phosphate) (10).

Starting from 25 mg (0.083 mmol) of 2'-deoxy-2-(methylthio)-*N*⁶-methyladenosine, **40**, and following the general procedure, we obtained 7.5 mg (0.014 mmol, 17% yield) of **10**: ¹H NMR (D₂O) δ 2.55 (3H, s, SCH₃), 2.67–2.86 (2H, m, CH₂-2'), 3.02 (3H, s, NHCH₃), 3.95 (2H, m, CH₂-5'), 4.37 (1H, bs, H-4'), 4.88 (1H, m, H-3'), 6.47 (1H, t, *J* = 6.9 Hz, H-1'), 8.29 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.06 (d, *J* = 9.0 Hz, 3'-P), 0.73 (bs, 5'-P).

2'-Deoxy-2-(ethylthio)adenosine 3',5'-Bis(diammonium phosphate) (11).

Starting from 22 mg (0.071 mmol) of 2'-deoxy-2-(ethylthio)adenosine, **52**, and following the general procedure, we obtained 7.6 mg (0.016 mmol, 23% yield) of **11**: ¹H NMR (D₂O) δ 1.50 (3H, t, *J* = 7.3 Hz, CH₃CH₂S), 2.85 (1H, m, CH₂-2'), 3.05 (1H, m, CH₂-2'), 3.32 (2H, q, *J* = 7.81 Hz, CH₃CH₂S), 4.18 (2H, m, CH₂-5'), 4.58 (1H, m, H-4'), 5.10 (1H, m, H-3'), 6.72 (1H, t, *J* = 6.5 Hz, H-1'), 8.49 (1H, s, H-8); ³¹P NMR (D₂O) δ 1.48 (d, *J* = 9.1 Hz, 5'-P), 1.02 (d, *J* = 14.1 Hz, 3'-P).

2'-Deoxy-2-(ethylthio)-*N*⁶-methyladenosine 3',5'-Bis(diammonium phosphate) (12).

Starting from 20 mg (0.061 mmol) of 2'-deoxy-2-(ethylthio)-*N*⁶-methyladenosine, **41**, and following the general procedure, we obtained 6.8 mg (0.014 mmol, 23% yield) of **12**: ¹H NMR (D₂O) δ 1.49 (3H, t, *J* = 7.7 Hz, CH₃CH₂S), 2.85–3.01 (2H, m, CH₂-2'), 3.22 (3H, s, NHCH₃), 3.32 (2H, q, *J* = 7.6 Hz, CH₃CH₂S), 4.06 (2H, m, CH₂-5'), 4.56 (1H, m, H-4'), 5.12 (1H, m, H-3'), 6.69 (1H, t, *J* = 6.8 Hz, H-1'), 8.55 (1H, s, H-8); ³¹P NMR (D₂O) δ 3.97 (s, 5'-P), 3.43 (s, 3'-P).

2'-Deoxy-2-(propylthio)adenosine 3',5'-Bis(diammonium phosphate) (13).

Starting from 39.6 mg (0.122 mmol) of 2-(propylthio)-2'-deoxyadenosine, **53**, and following the general procedure, we obtained 14.2 mg (0.026 mmol, 21.3% yield) of **13**: ¹H NMR (D₂O) δ 0.98 (3H, t, *J* = 6.8 Hz, CH₃CH₂CH₂S), 1.66–1.78 (2H, m, CH₃CH₂CH₂S), 2.69–2.75 (1H, m, CH₂-2'), 2.81–2.93 (1H, m, CH₂-2'), 3.16 (2H, t, *J* = 6.8 Hz, CH₃CH₂CH₂S), 4.06 (2H, m, CH₂-5'), 4.43 (1H, bs, H-4'), 4.97 (1H, bs, H-3'), 6.51 (1H, t,

$J = 6.8$ Hz, H-1'), 8.32 (1H, s, H-8); ^{31}P NMR (D_2O) 0.54 (s, 5'-P), -0.22 (d, $J = 1.8$ Hz, 3'-P).

2'-Deoxy-2-(propylthio)- N^6 -methyladenosine 3',5'-Bis(diammonium phosphate) (14).

Starting from 31.0 mg (0.091 mmol) of N^6 -methyl-2-(propylthio)-2'-deoxyadenosine, **42**, and following the general procedure, we obtained 5.0 mg (0.009 mmol, 10% yield) of **14**: ^1H NMR (D_2O) δ 0.96 (3H, t, $J = 6.8$ Hz, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}$), 1.64–1.71 (2H, m, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}$) 2.16–2.73 (1H, m, CH_2 -2'), 2.78–2.87 (1H, m, CH_2 -2'), 2.98 (3H, s, NHCH_3), 3.07 (2H, t, $J = 6.8$ Hz, $\text{CH}_3\text{CH}_2\text{CH}_2\text{S}$), 4.03 (2H, m, CH_2 -5'), 4.40 (1H, bs, H-4'), 4.94 (1H, bs, H-3') 6.40 (1H, t, $J = 5.8$ Hz, H-1'), 8.20 (1H, s, H-8); ^{31}P NMR (D_2O) δ 0.86 (bs, 5'-P), 0.18 (bs, 3'-P).

2-(Allylthio)-2'-deoxy- N^6 -methyladenosine 3',5'-Bis(diammonium phosphate) (15).

Starting from 20 mg (0.084 mmol) of 2-(allylthio)-2'-deoxy- N^6 -methyladenosine, **43**, and following the general procedure, we obtained 5.8 mg (0.117 mmol, 13% yield) of **15**: ^1H NMR (D_2O) δ 2.89 (2H, m, CH_2 -2'), 3.17 (3H, s, NHCH_3), 3.97 (2H, m, $\text{CH}_2=\text{CHCH}_2\text{S}$), 4.17 (2H, m, CH_2 -5'), 4.55 (1H, m, H-4'), 5.09 (1H, m, H-3'), 5.27 (1H, d, $J = 10.0$ Hz, $\text{CH}_2=\text{CHCH}_2\text{S}$), 5.51 (1H, d, $J = 12.0$ Hz, $\text{CH}_2=\text{CHCH}_2\text{S}$), 6.20 (1H, m, $\text{CH}_2=\text{CHCH}_2\text{S}$), 6.60 (1H, t, $J = 6.0$ Hz, H-1'), 8.39 (1H, s, H-8); ^{31}P NMR (D_2O) δ 1.31 (bs, 5'-P), 0.78 (bs, 3'-P).

2'-Deoxy-2-(hexylthio)- N^6 -methyladenosine 3',5'-Bis(diammonium phosphate) (16).

Starting from 28 mg (0.073 mmol) of 2'-deoxy-2-(hexylthio)- N^6 -methyladenosine, **44**, and following the general procedure, we obtained 10.8 mg (0.018 mmol, 25% yield) of **16**: ^1H NMR (D_2O) δ 0.82 (3H, m, CH_3CH_2), 1.26 (4H, m, CH_2CH_2), 1.40 (2H, m, CH_2), 1.72 (2H, m, $\text{CH}_2\text{CH}_2\text{S}$), 2.68–2.88 (2H, m, CH_2 -2'), 3.05 (3H, bs, NHCH_3), 3.15 (2H, m, CH_2S), 4.03 (2H, m, CH_2 -5'), 4.40 (1H, bs, H-4'), 4.94 (1H, m, H-3'), 6.47 (1H, t, $J = 6.8$ Hz, H-1'), 8.30 (1H, s, H-8); ^{31}P NMR (D_2O) δ 1.44 (s, 3'-P); 1.90, (s, 5'-P).

2-Amino-2'-deoxy- N^6 -methyladenosine 3',5'-Bis(diammonium phosphate) (17a).

Starting from 15 mg (0.053 mmol) of 2-amino-2'-deoxy- N^6 -methyladenosine, **48**, and following the general procedure, we obtained 4.4 mg (0.01 mmol, 19% yield) of **17a**: ^1H NMR (D_2O) δ 2.50 (1H, m, CH_2 -2'), 2.67 (1H, m, CH_2 -2'), 2.99 (1H, s, NHCH_3), 3.96 (2H, m, CH_2 -5'), 4.21 (1H, m, H-4'), 4.85 (1H, m, H-3'), 6.27 (1H, t, $J = 6.6$ Hz, H-1'), 8.06 (1H, s, H-8); ^{31}P NMR (D_2O) δ 0.99 (s, 5'-P), 0.49 (bs, 3'-P).

2'-Deoxyguanosine 3',5'-Bis(diammonium phosphate) (17b).

Starting from 50 mg (0.22 mmol) of 2'-deoxyguanosine and following the general procedure, we obtained 39.4 mg (0.086 mmol, 39% yield) of **17b**: ^1H NMR (D_2O) δ 2.40 (1H, m, CH_2 -2'), 2.55 (1H, m, CH_2 -2'), 4.08 (2H, m, CH_2 -5'), 4.36 (1H, bs, H-4'), 4.80 (H-3' under D_2O peak), 5.93 (1H, d, $J = 8.8$ Hz, H-5), 6.37 (1H, t, $J = 6.8$ Hz, H-1'), 7.98 (1H, d, $J = 8.8$ Hz, H-6); ^{31}P NMR (D_2O) δ 0.89, (s, 5'-P); 0.31 (s, 3'-P).

2'-Deoxy-8-methyladenosine 3',5'-Bis(diammonium phosphate) (18).

Starting from 12.0 mg (0.045 mmol) of 8-methyl-2'-deoxyadenosine(30 and following the general procedure, we obtained 2.0 mg (0.004 mmol, 8.9% yield) of **18**: ^1H NMR (D_2O) δ 2.50–2.59 (1H, m, $\text{CH}_2\text{-2}'$), 3.02–3.20 (1H, m, $\text{CH}_2\text{-2}'$), 2.68 (3H, s, 8- CH_3), 4.06–4.10 (2H, m, $\text{CH}_2\text{-5}'$), 4.30 (1H, bs, H-4'), 4.90 (1H, m, H-3'), 6.49 (1H, t, J = 6.8 Hz, H-1'), 8.20 (1H, s, H-2); ^{31}P NMR (D_2O) δ 1.88 (bs, 5'-P), 1.62 (bs, 3'-P).

2'-Deoxy-8-vinyladenosine 3',5'-Bis(diammonium phosphate) (19).

Starting from 15.0 mg (0.054 mmol) of 8-vinyl-2'-deoxyadenosine(30 and following the general procedure, we obtained 3.7 mg (0.0073 mmol, 13.6% yield) of **19**: ^1H NMR(D_2O) δ 2.50–2.55 (1H, m, $\text{CH}_2\text{-2}'$), 2.95–3.10 (1H, m, $\text{CH}_2\text{-2}'$), 4.01–4.05 (2H, m, $\text{CH}_2\text{-5}'$), 4.30 (1H, bs, H-4'), 4.91 (1H, m, H-3'), 5.84 (1H, d, J = 10.7 Hz, vinyl), 6.37 (1H, d, J = 16.6 Hz, vinyl), 6.56 (1H, t, J = 5.8 Hz, H-1'), 7.20 (1H, dd, J = 16.6, 10.7 Hz, vinyl), 8.20 (1H, s, H-2); ^{31}P NMR (D_2O) δ 3.85 (bs, 5'-P), 3.36 (bs, 3'-P).

2'-Deoxy-8-O-methyladenosine 3',5'-Bis(diammonium phosphate) (20).

Starting from 24 mg (0.085 mmol) of 2'-deoxy-8-*O*-methyl-adenosine, **56**, and following the general procedure, we obtained 4.2 mg (0.009 mmol, 17% yield) of **20**: ^1H NMR (D_2O) δ 2.42 (1H, m, $\text{CH}_2\text{-2}'$), 3.20 (1H, m, $\text{CH}_2\text{-2}'$), 3.89 (3H, s, OCH_3), 4.0–4.35 (3H, m, $\text{CH}_2\text{-5}'$ and H-4'), 5.1 (1H, m, H-3'), 6.61 (1H, t, J = 6.4 Hz, H-1'), 8.10 (1H, s, H-2); ^{31}P NMR (D_2O) δ 0.78 (s, 5'-P), 0.25 (bs, 3'-P).

2'-Deoxy-8-(methylthio)adenosine 3',5'-Bis(diammonium phosphate) (21).

Starting from 25 mg (0.084 mmol) of 2'-deoxy-8-(methylthio)adenosine, **57**, and following the general procedure, we obtained 14.2 mg (0.031 mmol, 37% yield) of **21**: ^1H NMR (D_2O) δ 2.45 (1H, m, $\text{CH}_2\text{-2}'$), 2.72 (3H, s, SCH_3), 3.21 (1H, m, $\text{CH}_2\text{-2}'$), 4.08 (2H, m, $\text{CH}_2\text{-5}'$), 4.25 (1H, m, H-4'), 5.0 (1H, m, H-3'), 6.5 (1H, t, J = 6.5 Hz, H-1'), 8.15 (1H, s, H-2); ^{31}P NMR (D_2O) δ 0.98 (bs, 5'-P), 0.31 (bs, 3'-P).

2'-Deoxy-8-(methylamino)adenosine 3',5'-Bis(diammonium phosphate) (22).

Starting from 28.1 mg (0.1 mmol) of 2'-deoxy-8-(methylamino)adenosine, **58**, and following the general procedure, we obtained 2.4 mg (0.0055 mmol, 5.5% yield) of **22**: ^1H NMR (D_2O) δ 2.53 (1H, m, $\text{CH}_2\text{-2}'$), 3.09 (3H, s, NHCH_3), 3.24 (1H, m, $\text{CH}_2\text{-2}'$), 4.12 (2H, m, $\text{CH}_2\text{-5}'$), 4.30 (1H, m, H-4'), 4.99 (1H, m, H-3'), 6.47 (1H, t, J = 7.4 Hz, H-1'), 8.15 (1H, s, H-2); ^{31}P NMR (D_2O) δ 0.91 (s, 5'-P), 0.25 (bs, 3'-P).

2'-Deoxy-4'-thioadenosine 3',5'-Bis(diammonium phosphate) (23).

Starting from 12 mg (0.045 mmol) of 2'-deoxy-4'-thioadenosine, **62**, and following the general procedure, we obtained 2.4 mg (0.0056 mmol, 13% yield) of **23**: ^1H NMR (D_2O) δ 2.59 (2H, m, $\text{CH}_2\text{-2}'$), 3.97 (2H, m, $\text{CH}_2\text{-5}'$), 4.32 (1H, m, H-4'), 4.95 (1H, m, H-3'), 6.30 (1H, t, J = 7.0 Hz, H-1'), 8.06 (1H, s, H-2), 8.18 (1H, s, H-8); ^{31}P NMR (D_2O) δ 0.55 (s, 5'-P), -0.20 (d, J = 2.4 Hz, 3'-P).

(1*R*,2*R*,4*R*)-4-(9*H*-Adenin-9-yl)-2-(phosphatomethyl)cyclopentan-1-yl Phosphate (24).

Starting from 6.0 mg (0.024 mmol) of carbocyclic 2'-deoxyadenosine, **56**, (27 and following the general procedure, we obtained 2.4 mg (0.0059 mmol, 24.5% yield) of **24**, the carbocyclic equivalent of 2'-deoxyadenosine 3',5'-bis(diammonium phosphate): ¹H NMR (D₂O) δ 1.98 (1H, m, CH₂-2'), 2.5 (3H, m, CH₂-2' and CH₂-6'), 4.03 (2H, m, CH₂-5'), 4.68 (1H, m, H-4'), 5.12 (1H, m, H-3'), 5.25 (1H, m, *J* = 5.5 Hz, H-1'), 8.28 (1H, s, H-2), 8.34 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.94 (s, 5'-P), -0.07 (s, 3'-P).

(1*R*,2*R*,4*R*)-4-(9*H*-2-Amino-*N*⁶-methyladenin-9-yl)-2(phosphatomethyl)cyclopentan-1-yl Phosphate (25).

Starting from 15 mg (0.054 mmol) of the carbocyclic equivalent of 2-amino-2'-deoxy-*N*⁶-methyladenosine, **61**, and following the general procedure, we obtained 2.4 mg (0.0055 mmol, 10% yield) of **25**, the carbocyclic equivalent of 2-amino-2'-deoxy-*N*⁶-methyladenosine 3',5'-bis(diammonium phosphate): ¹H NMR (D₂O) δ 1.87 (1H, m, CH₂-2'), 2.29 (2H, m, CH₂-6'), 2.54 (1H, m, CH₂-2'), 3.13 (3H, s, NHCH₃), 3.99 (2H, m, CH₂-5'), 4.40 (1H, m, H-4'), 4.96 (2H, m, H-3' and H-1'), 8.00 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.92 (bs, 5'-P), 0.42 (s, 3'-P).

2'-Deoxy-4'-thioadenosine *S*-Oxide 5'-Mono(diammonium phosphate) (26).

Starting from 14.0 mg (0.049 mmol) of 2'-deoxy-4'-thioadenosine *S*-oxide, **63**, and following the general procedure, we obtained 0.50 mg (0.001 mmol, 2.0% yield) of **26**: ¹H NMR (D₂O) δ 2.79–2.95 (1H, m, H-2'), 3.11–3.27 (1H, m, H-2'), 3.51–3.66 (2H, m, H-5'), 3.72–3.77 (1H, m, H-4'), 4.29–4.34 (1H, m, H-3'), 6.18–6.38 (1H, m, H-1'), 8.30 (1H, s, H-2) 8.37 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.46, 0.34 (2s, mixture of diastereomers).

2'-Deoxy-5'-O-phosphonylmethyladenosine 3'-Phosphate (tetrammonium salt) (27).

Starting from 15 mg (0.043 mmol) of 2'-deoxy-5'-[diethyl(methylphosphonyl)]adenosine, **64**, and following the general procedure, we obtained 1.8 mg (0.0042 mmol, 9.8% yield) of **27**. Cleavage of the phosphonate esters was verified by NMR and MS: ¹H NMR (D₂O) δ 2.83 (2H, m, CH₂-2'), 4.10 (4H, m, CH₂-5' and CH₂-P), 4.47 (1H, m, H-4'), 5.10 (1H, m, H-3'), 6.58 (1H, t, *J* = 7.9 Hz, H-1'), 8.28 (1H, s, H-2), 8.51 (1H, s, H-8); ³¹P NMR (D₂O) δ 27.49 (s, 5'-CH₂P), 3.31 (s, 3'-P).

2'-Deoxyadenosine 3',5'-Bis(ammonium methyl phosphate) (28).

Starting from 25 mg (0.1 mmol) of 2'-deoxyadenosine and following the general procedure using methyl dichlorophosphate (59.6 mg, 41.13 μL, 0.4 mmol), we obtained 9.8 mg (0.018 mmol, 22% yield) of **28**: ¹H NMR (D₂O) δ 2.64 (1H, m, CH₂-2'), 2.86 (1H, m, CH₂-2'), 3.42 (3H, d, *J* = 10.8 Hz, CH₃OP), 3.58 (3H, d, *J* = 10.8 Hz, CH₃OP), 4.02 (2H, m, nCH₂-5'), 4.28 (1H, m, H-4'), 4.53 (1H, m, H-3'), 6.46 (1H, t, *J* = 6.9 Hz, H-1'), 8.18 (1H, s, H-2), 8.37 (1H, s, H-8); ³¹P NMR (D₂O) δ 3.30 (bs, 5'-P), 1.79 (d, *J* = 2.4 Hz, 3'-P).

2'-Deoxy-*N*⁶-methyladenosine 3',5'-Cyclic-diphosphate (diammonium salt) (29a) and 2'-Deoxy-*N*⁶-methyladenosine 3',5'-Cyclic-tetraphosphate (tetraammonium salt) (29b).

A solution of 20 mg (0.04 mmol) of **2** in anhydrous DMF was evaporated under reduced pressure below 30 °C, and this drying procedure was repeated three times. The residue was resuspended in 2 mL of anhydrous DMF under nitrogen atmosphere, and 38 μ L (0.16 mmol) of tributylamine was added at room temperature. The mixture was stirred for 30 min, and a solution of 33 mg (0.2 mmol) of carbonyldiimidazole was added. The mixture was stirred for 12 h at room temperature before the excess carbonyldiimidazole was quenched by addition of 0.05 mL of methanol, and the mixture was stirred for 30 min. A solution of 0.091 g of bis(tributylammonium)-pyrophosphate (0.2 mmol) in 2 mL of anhydrous DMF was added at room temperature, and the mixture was stirred for 42 h. The reaction mixture was evaporated under reduced pressure below 30 °C, and two products were purified by the ion-exchange column chromatography in the general procedure and semipreparative HPLC using SMT OD-5–60 C18 column with a linear gradient elution of 1.0 M triethylammonium acetate solution and CH₃CN (95/5–40/60 for 30 min). After evaporation of the pure fraction under reduced pressure, the products were redissolved in 0.5 M ammonium bicarbonate solution, and repeated lyophilization with water gave 3.5 mg of **29a** (yield 20%) and 1.2 mg of **29b** (yield 5%).

29a: ¹H NMR (D₂O) δ 2.74–2.84 (1H, m, CH₂-2'), 2.97–3.02 (1H, m, CH₂-2'), 3.04 (3H, s, NHCH₃), 3.83–3.96 (1H, m, H-4'), 4.21–4.39 (2H, m, H-5'), 5.19 (1H, pen, J = 7.8 Hz, H-3'), 6.39–6.42 (1H, m, H-1'), 8.20 (1H, s, H-2), 8.23 (1H, s, H-8); ³¹P NMR (D₂O) δ –12.45 (dd, J = 8.5, 24.5 Hz, 3'-CHOP-), –11.71 (2, dd, J = 10.3, 18.6, 24.4 Hz, 5'-CH₂OP-), with proton decoupling off mode.

29b: ¹H NMR (D₂O) δ 2.75–2.84 (1H, m, CH₂-2'), 2.90–2.99 (1H, m, CH₂-2'), 3.09 (3H, s, NHCH₃), 4.10–4.16 (1H, m, H-4'), 4.29–4.40 (2H, m, H-5'), 5.27 (1H, pen, J = 6.8 Hz, H-3'), 6.50 (1H, t, J = 5.8 Hz, H-1'), 8.26 (1H, s, H-2), 8.42 (1H, s, H-8); ³¹P NMR (D₂O) δ –23.38 to –23.22 (2P, m), –12.01 to –11.80 (m), –11.05 to –10.95 (m), with proton decoupling off mode; Negative API-ES Mass 566 (M - H).

3'-Azido-3'-deoxyxyloadenosine 2',5'-Bis(diammonium phosphate) (30).

Starting from 25 mg (0.085 mmol) of 3'-azido-3'-deoxyxyloadenosine and following the general procedure, we obtained 4.9 mg (0.011 mmol, 13% yield) of **30**: ¹H NMR (D₂O) δ 3.1 (1H, m, H-2'), 3.64 (1H, m, H-3'), 4.30 (2H, m, CH₂-5'), 4.53 (1H, m, H-4'), 6.12 (1H, bs, H-1'), 8.25 (1H, s, H-2), 8.48 (1H, s, H-8); ³¹P NMR (D₂O) δ 1.37 (bs, 5'-P), 0.55 (bs, 3'-P).

3'-Azido-3'-deoxyxyloadenosine 2'-Monophosphate 5'Triphosphate (hexaammonium salt) (31).—Starting from 25 mg (0.085 mmol) of 3'-azido-3'-

deoxyxyloadenosine and following the general procedure, we obtained 1.7 mg (0.0028 mmol, 3.0% yield) of **31**: ¹H NMR (D₂O) δ 3.14 (1H, m, H-2'), 3.65 (1H, m, H-3'), 4.35 (2H, m, CH₂-5'), 4.56 (1H, M, H-4'), 6.13 (1H, bs, H-1'), 8.28 (1H, s, H-2), 8.51 (1H, s, H-8); ³¹P NMR (D₂O) δ 0.43 (s, 3'-P), –10.43 (d, J = 19.5 Hz, 5'-P γ), –11.11, –11.27 (2t, J = 6.1 Hz, 5'-P β), –22.76 (t, J = 19.7 Hz, 5'-PR).

2'-Deoxyuridine 3',5'-Bis(diammonium phosphate) (32).

Starting from 50 mg (0.22 mmol) of 2'-deoxyuridine and following the general procedure, we obtained 39.4 mg (0.086 mmol, 39% yield) of **32**: ^1H NMR (D_2O) δ 2.40 (1H, m, $\text{CH}_2\text{-}2'$), 2.55 (1H, m, $\text{CH}_2\text{-}2'$), 4.08 (2H, m, $\text{CH}_2\text{-}5'$), 4.36 (1H, bs, H-4'), 4.80 (H3' under D_2O peak), 5.93 (1H, d, $J = 8.8$ Hz, H-5), 6.37 (1H, t, $J = 6.8$ Hz, H-1'), 7.98 (1H, d, $J = 8.8$ Hz, H-6); ^{31}P NMR (D_2O) δ 0.89 (s, 5'-P), 0.31 (s, 3'-P).

Thymidine 3',5'-Bis(diammonium phosphate) (33).

Starting from 50 mg (0.22 mmol) of thymidine and following the general procedure, we obtained 39.4 mg (0.086 mmol, 39% yield) of **33**: ^1H NMR (D_2O) δ 2.40 (1H, m, $\text{CH}_2\text{-}2'$), 2.55 (1H, m, $\text{CH}_2\text{-}2'$), 4.08 (2H, m, $\text{CH}_2\text{-}5'$), 4.36 (1H, bs, H4'), 4.80 (H3' under D_2O peak), 5.93 (1H, d, $J = 8.8$ Hz, H5), 6.37 (1H, t, $J = 6.8$ Hz, H1'), 7.98 (1H, d, $J = 8.8$ Hz, H6); ^{31}P NMR (D_2O) δ 1.04 (s, 5'-P), 0.75 (s, 3'-P).

5-Fluoro-2'-deoxyuridine 3',5'-Bis(diammonium phosphate) (34).

Starting from 20 mg (0.081 mmol) of 5-fluoro-2'-deoxyuridine and following the general procedure, we obtained 8.9 mg (0.022 mmol, 27% yield) of **34**: ^1H NMR (D_2O) δ 2.38 (1H, m, $\text{CH}_2\text{-}2'$), 2.55 (1H, m, $\text{CH}_2\text{-}2'$), 4.08 (2H, m, $\text{CH}_2\text{-}5'$), 4.35 (1H, m, H-4'), 4.94 (1H, m, H-3'), 6.35 (1H, bs, H-1'), 8.17 (1H, s, H-5); ^{31}P NMR (D_2O) δ 1.52 (s, 5'-P), 1.19 (s, 3'-P).

2'-Deoxycytidine 3,5'-Bis(diammonium phosphate) (35).

Starting from 20 mg (0.087 mmol) of 2'-deoxycytidine and following the general procedure, we obtained 12 mg (0.031 mmol, 36% yield) of **35**: ^1H NMR (D_2O) δ 2.41 (1H, m, $\text{CH}_2\text{-}2'$), 2.65 (1H, m, $\text{CH}_2\text{-}2'$), 4.11 (2H, m, $\text{CH}_2\text{-}5'$), 4.42 (1H, bs, H-4'), 4.85 (1H, m, H-3'), 6.37 (1H, t, $J = 6.2$ Hz, H-1'), 8.07 (1H, d, $J = 8.0$ Hz, 1H), 8.18 (d, $J = 7.5$ Hz, 1H); ^{31}P NMR (D_2O) δ 0.51 (s, 5'-P), -0.13 (s, 3'-P).

1',5'-Anhydro-2'-(adenin-9-yl)-2',3'-dideoxy-D-arabino-hexitol 4',6'-Bis(diammonium phosphate) (36).

Starting from 19.2 mg (0.072 mmol) of 1',5'-anhydro-2'-(adenin-9-yl)-2',3'-dideoxy-D-arabino-hexitol(25 and following the general phosphorylation procedure, we obtained 0.50 mg (0.001 mmol, 1.4% yield) of **36**: ^1H NMR (D_2O) δ 2.04–2.74 (2H, m, $\text{CH}_2\text{-}3'$), 3.57–3.60 (1H, m, H-5'), 3.69–3.72 (1H, m, H-4'), 4.09 (2H, bs, $\text{CH}_2\text{-}6'$), 4.11–4.33 (2H, m, $\text{CH}_2\text{-}1'$), 4.93 (1H, bs, H-2'), 8.23 (1H, s, H-2), 8.51 (1H, s, H-8); ^{31}P NMR (D_2O) δ 3.28, 1.75 (2s).

2-Chloro-2'-deoxy-3',5'-di-O-acetyladenosine (38).

A mixture of commercial 2-chloro-2'-deoxyadenosine (**37**; 285 mg, 1 mmol), pyridine (3 mL), and acetic anhydride (2 mL) was stirred at room temperature for 2 h under nitrogen atmosphere. The reaction mixture was evaporated to dryness and chromatographed by pTLC ($\text{CHCl}_3/\text{MeOH}$, 95/5) to obtain **38** as a white solid (300 mg, 0.81 mmol, 81% yield): MS (CI-NH_3) 370 ($\text{M}^+ + 1$), 387 ($\text{M} + \text{NH}_4^+$); ^1H NMR (CDCl_3) δ 2.11 (3H, s, CH_3CO), 2.14 (3H, s, CH_3CO), 2.61–2.69 (1H, m, $\text{CH}_2\text{-}2'$), 2.76–2.86 (1H, m, $\text{CH}_2\text{-}2'$), 4.38 (3H, m,

CH₂-5' and H-4'), 5.39 (1H, m, H-3'), 6.04 (2H, s, NH₂), 6.45 (1H, t, *J* = 6.8 Hz, H-1'), 7.99 (1H, s, H-8).

2-Chloro-*N*⁶-methyl-2'-deoxyadenosine (39).

A flame dried 25-mL round-bottom flask fitted with a reflux condenser was charged with **38** (250 mg, 0.68 mmol), isoamyl nitrite (2 mL), and diiodomethane (2 mL) under nitrogen atmosphere. The mixture was stirred at 85 °C for 1 h. The solvent was removed with nitrogen purging, and the crude residue was stirred with aqueous methylamine (5 mL, 40% solution) for 1 h. The water was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to furnish **39** as a colorless solid (85.4 mg, 0.29 mmol, 42% yield): MS (CI-NH₃) 300 (*M*⁺ + 1); ¹H NMR (CD₃OD) δ 2.35–2.43 (1H, m, CH₂-2'), 2.68, 2.68–2.80 (1H, m, CH₂-2'), 3.06 (3H, bs, NHCH₃), 3.10 (2H, m, CH₂S), 3.79 (2H, m, CH₂-5'), 4.04 (1H, m, H-4'), 4.57 (1H, m, H-3'), 6.34 (1H, t, *J* = 6.8 Hz, H-1'), 8.20 (1H, s, H-8).

2-(Methylthio)-*N*⁶-methyl-2'-deoxyadenosine (40).

To a solution of 2-chloro-2'-deoxy-*N*⁶-methyladenosine (**39**; 50 mg, 0.17 mmol) in dry DMF (3 mL) was added sodium thiomethoxide (35 mg, 0.5 mmol), and the reaction mixture was stirred and heated in a sealed tube at 110 °C for 4 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to give **40** as a colorless solid (40 mg, 0.13 mmol, 76% yield): MS (CI-NH₃) 312 (*M*⁺ + 1); ¹H NMR (CD₃OD) δ 2.35–2.42 (1H, m, CH₂-2'), 2.65 (3H, s, CH₃S), 2.78–2.88 (1H, m, CH₂-2'), 3.09 (3H, bs, NHCH₃), 3.71–3.84 (2H, m, CH₂-5'), 4.01–4.03 (1H, m, H-4'), 4.56–4.58 (1H, m, H-3'), 6.36 (1H, t, *J* = 6.8 Hz, H-1'), 8.09 (1H, s, H-8).

2-(Ethylthio)-*N*⁶-methyl-2'-deoxyadenosine (41).

To a suspension of potassium *tert*-butoxide (112 mg, 1 mmol) in dry DMF (3 mL) in a sealed tube was added ethanethiol (60 mg, 71 μL, 1 mmol), and the reaction mixture was stirred at room temperature for 30 min. 2-Chloro-2'-deoxy-*N*⁶-methyladenosine (**39**; 50 mg, 0.17 mmol) in dry DMF (1 mL) was added and heated at 110 °C for 4 h while stirring. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to provide **41** as a colorless solid (39 mg, 0.12 mmol, 70% yield): MS (CI-NH₃) 326 (*M*⁺ + 1); ¹H NMR (CD₃OD) δ 1.45 (3H, t, *J* = 6.9 Hz, CH₃CH₂S), 2.45–2.52 (1H, m, CH₂-2'), 2.88–2.97 (1H, m, CH₂-2'), 3.10 (3H, s, N-CH₃), 3.22 (2H, q, *J* = 6.4 Hz, CH₃CH₂S), 3.77–3.90 (2H, m, CH₂-5'), 4.09 (1H, bs, H-4'), 4.64 (1H, bs, H-3'), 6.44 (1H, t, *J* = 5.9 Hz, H-1'), 8.03 (2H, bs, NH₂), 8.23 (1H, s, H-8).

2-(Propylthio)-*N*⁶-methyl-2'-deoxyadenosine (42).

To a suspension of potassium *tert*-butoxide (112 mg, 1 mmol) in dry DMF (3 mL) in a sealed tube was added propanethiol (72 mg, 86 μL, 1 mmol), and the reaction mixture was stirred at room temperature for 30 min. 2-Chloro-2'-deoxy-*N*⁶-methyladenosine (**39**; 50 mg, 0.17 mmol) in dry DMF (1 mL) was added and heated at 110 °C for 4 h while stirring. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to provide **42** as a colorless solid (46 mg, 0.14 mmol, 80%

yield): MS (CINH₃) 340 (M⁺ + 1); ¹H NMR (CD₃OD) δ 1.13 (3H, t, *J* = 6.8 Hz, CH₃CH₂CH₂S), 1.83–1.87 (2H, m, CH₃CH₂CH₂S), 2.39–2.42 (1H, m, CH₂-2'), 2.84–2.92 (1H, m, CH₂-2'), 3.17 (3H, s, N-CH₃), 3.19 (2H, bs, CH₃CH₂CH₂S), 3.80–3.92 (2H, m, CH₂5'), 4.12 (1H, bs, H-4'), 4.62 (1H, bs, H-3'), 6.42 (1H, t, *J* = 6.4 Hz, H-1'), 8.17 (1H, s, H-8).

2-(Allylthio)-N⁶-methyl-2'-deoxyadenosine (43).

To a suspension of potassium *tert*-butoxide (112 mg, 1 mmol) in dry DMF (3 mL) in a sealed tube was added allylthiol (70 mg, 1 mmol), and the reaction mixture was stirred at room temperature for 30 min. 2-Chloro-2'-deoxy-N⁶-methyladenosine (**39**; 50 mg, 0.17 mmol) in dry DMF (1 mL) was added and heated at 110 °C for 4 h while stirring. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to provide **43** as a colorless solid (41 mg, 0.12 mmol, 72% yield): MS (CI-NH₃) 338 (M⁺ + 1); ¹H NMR (CD₃OD) δ 2.32–2.37 (1H, m, CH₂-2'), 2.72–2.80 (1H, m, CH₂-2'), 3.09 (3H, s, NCH₃), 3.68–3.72 (2H, m, CH₂d CHCH₂S), 4.01 (1H, bs, H-4'), 4.55 (1H, m, H-3'), 5.05 (1H, d, *J* = 10.5 Hz, CH₂d CHCH₂S), 5.31 (1H, d, *J* = 12.6 Hz, CH₂d CHCH₂S), 5.80 (1H, m, CH₂CHCH₂S), 6.35 (1H, t, *J* = 5.6 Hz, H-1'), 8.11 (1H, s, H-8).

2-(Hexylthio)-N⁶-methyl-2'-deoxyadenosine (44).

To a suspension of potassium *tert*-butoxide (146 mg, 1.3 mmol) in dry DMF (3 mL) in a sealed tube was added hexanethiol (183 μ L, 1.3 mmol), and the reaction mixture was stirred at room temperature for 30 min. To the reaction mixture was added a solution of 2-chloro-2'-deoxy-N⁶-methyladenosine (**39**; 38 mg, 0.13 mmol) in dry DMF (2 mL), and the mixture was stirred and heated at 110 °C for 4 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to obtain the desired compound 2'-deoxy-2-(hexylthio)-N⁶-methyladenosine (**44**) as a colorless solid (35 mg, 0.091 mmol, 70% yield): MS (CI-NH₃) 382 (M⁺ + 1); ¹H NMR (CD₃OD) δ 0.87 (3H, m, CH₃CH₂), 1.29 (4H, m, CH₂CH₂), 1.38 (2H, m, CH₂), 1.67 (2H, m, CH₂CH₂S), 2.29–2.37 (1H, m, CH₂-2'), 2.68–2.78 (1H, m, CH₂-2'), 3.05 (3H, bs, NHCH₃), 3.10 (2H, m, CH₂S), 3.76 (2H, m, CH₂-5'), 4.00 (1H, m, H-4'), 4.51 (1H, m, H-3'), 6.31 (1H, t, *J* = 6.8 Hz, H-1'), 8.05 (1H, s, H-8).

2'-Deoxy-3',5'-di-O-acetylguanosine (46).

A mixture of commercial 2'-deoxyguanosine (267 mg, 1 mmol), pyridine (4 mL), and acetic anhydride (2 mL) was heated while stirring at 65 °C for 4 h under nitrogen atmosphere. The reaction mixture was cooled, quenched with methanol, and evaporated to dryness. The crude residue was purified by flash column chromatography (CHCl₃/MeOH, 95/5) to obtain **46** as a white solid (263 mg, 0.72 mmol, 75% yield): MS (CI-NH₃) 352 (M⁺ + 1), 369 (M + NH₄⁺); ¹H NMR (CD₃OD) δ 2.06 (3H, s, CH₃-CO), 2.11 (3H, s, CH₃CO), 2.53–2.60 (1H, m, CH₂-2'), 2.96–3.01 (1H, m, CH₂-2'), 3.32 (1H, bs, H-4'), 4.25–4.36 (2H, m, CH₂-5'), 5.44 (1H, bs, H-3'), 6.27 (1H, t, *J* = 6.4 Hz, H-1'), 7.87 (1H, s, H-8).

6-Chloro-9-(2-deoxy-3,5-di-*O*-acetyl- β -D-erythropentofuranosyl)guanine (47).

A flame-dried 50-mL round-bottom flask fitted with a reflux condenser was charged with **46** (351 mg, 1 mmol), predried tetraethylammonium chloride (183 mg, 1.1 mmol), freshly distilled *N,N*-dimethylaniline (122 mg, 1.28 mL, 1 mmol), and dry acetonitrile (5 mL) under nitrogen atmosphere while stirring followed by cooling the mixture in an ice bath. Phosphorus oxychloride (306 mg, 1.86 mL, 2 mmol) was added dropwise, and stirring was continued for 10 min at room temperature. The reaction mixture was then refluxed for 10 min. The solvent and volatile materials were evaporated under reduced pressure, and the resultant yellow oil was stirred with crushed ice for 15 min. The yellow oil was extracted with chloroform (5 $\times$ 15 mL), washed with saturated NaHCO₃ solution and cold water, dried over anhydrous Na₂SO₄, filtered, and evaporated to give a light-yellow syrup which was purified by flash column chromatography (CHCl₃/MeOH, 95/5) to furnish **47** as a light-yellow solid (164 mg, 0.44 mmol, 44% yield): MS (CI-NH₃) 370 (M⁺ + 1); ¹H NMR (CDCl₃) δ 2.11 (3H, s, CH₃CO), 2.16 (3H, s, CH₃CO), 2.67–2.74 (1H, m, CH₂-2'), 2.79–2.89 (1H, m, CH₂-2'), 4.39 (3H, bs, CH₂-5' and H-4'), 5.40 (1H, m, H-3'), 6.45 (1H, t, *J* = 6.9 Hz, H-1'), 8.34 (1H, s, H-8).

2-Amino-*N*⁶-methyl-2'-deoxyadenosine (48).

A mixture of 2-chloro-2'-deoxy-3',5'-di-*O*-acetyl-6-chloropurine riboside (**47**; 230 mg, 0.62 mmol) and 40% aqueous methylamine (5 mL) was stirred at room temperature for 2 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 95/5) to obtain the desired compound 2-chloro-2'-deoxy-*N*⁶-methyladenosine (**48**) as a white solid (113 mg, 0.40 mmol, 55% yield): MS (CI-NH₃) 281 (M⁺ + 1); ¹H NMR (CD₃OD) δ 2.28–2.33 (1H, m, CH₂-2'), 2.77–2.82 (1H, m, CH₂-2'), 3.04 (3H, s, N-CH₃), 3.71–3.88 (2H, m, CH₂-5'), 4.06 (1H, bs, H-4'), 4.56 (1H, bs, H-3'), 6.28 (1H, t, *J* = 5.7 Hz, H-1'), 7.87 (1H, s, H-8).

2-Amino-*N*⁶-methyl-2'-deoxy-3',5'-di-*O*-acetyladenosine (49).

A mixture of 2-amino-*N*⁶-methyl-2'-deoxyadenosine (**48**, 140 mg, 0.5 mmol), pyridine (2 mL), and acetic anhydride (1.5 mL) was stirred at room temperature for 4 h. The mixture was evaporated to dryness and chromatographed by pTLC (CHCl₃/MeOH, 95/5) to obtain **49** as a colorless solid (142 mg, 0.39 mmol, 78% yield): MS (CI-NH₃) 365 (M⁺ + 1); ¹H NMR (CDCl₃) δ 2.09 (3H, s, CH₃CO), 2.14 (3H, s, CH₃CO), 2.59–2.67 (1H, m, CH₂-2'), 2.89–2.99 (1H, m, CH₂-2'), 4.34–4.39 (3H, m, CH₂-5' and H-4'), 5.42–5.45 (1H, m, H-3'), 6.02 (2H, bs, NH₂), 6.44 (1H, t, *J* = 5.9 Hz, H-1'), 8.24 (1H, s, H-8).

2-Iodo-*N*⁶-methyl-2'-deoxyadenosine (50).

A flame-dried 25-mL round-bottom flask fitted with a reflux condenser was charged with compound **49** (140 mg, 0.38 mmol), isoamyl nitrite (1.5 mL) and diiodomethane (1.5 mL), under nitrogen atmosphere. The mixture was stirred at 85 °C for 1 h. The solvent was removed with nitrogen purging, and the crude residue was stirred with aqueous methylamine (5 mL, 40% solution) for 1 h. The water was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to furnish compound **50** as a colorless solid (71 mg, 0.18 mmol, 48% yield): MS (CI-NH₃) 392 (M⁺ + 1); ¹H NMR

(CD₃OD) δ 2.35–2.43 (1H, m, CH₂–2'), 2.69–2.80 (1H, m, CH₂–2'), 3.06 (3H, s, NCH₃), 3.71–3.82 (2H, m, CH₂–5'), 4.02–4.05 (1H, m, H-4'), 4.54–4.58 (1H, m, H-3'), 6.34 (1H, t, J = 5.95 Hz, H-1'), 8.20 (1H, s, H-8).

2-(Methylthio)-2'-deoxyadenosine (51).

To a solution of 2-chloro-2'-deoxyadenosine (**37**; 31 mg, 0.1 mmol) in dry DMF (2 mL) was added sodium thiomethoxide (70 mg, 1 mmol), and the mixture was stirred and heated in a sealed tube at 110 °C for 4 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 93/7) to afford **51** as a white solid (21 mg, 0.07 mmol, 70% yield): MS (CI-NH₃) 298 (M⁺ + 1); ¹H NMR (CD₃OD) δ 2.28–2.30 (1H, m, CH₂–2'); 2.76–2.85 (1H, m, CH₂–2'), 3.39 (3H, s, CH₃S), 3.52–3.68 (2H, m, CH₂–5'), 3.91 (1H, m, H-4'), 4.47 (1H, m, H-3'), 4.99 (1H, bs, OH), 5.38 (1H, bs, OH), 6.35 (1H, t, J = 5.7 Hz, H-1'), 7.41 (2H, bs, NH₂), 8.27 (1H, s, H-8).

2-(Ethylthio)-2'-deoxyadenosine (52).

To a suspension of potassium *tert*-butoxide (112 mg, 1 mmol) in dry DMF (2 mL) in a sealed tube was added ethanethiol (62 mg, 74 μ L, 1 mmol), and the reaction mixture was stirred at room temperature for 30 min. A solution of 2-chloro-2'-deoxy-*N*⁶-methyladenosine (**37**; 31 mg, 0.1 mmol) in dry DMF (1 mL) was added to the above mixture, and the reaction was stirred and heated at 110 °C for 4 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to afford **52** as a colorless solid (25 mg, 0.08 mmol, 80% yield): MS (CI-NH₃) 312 (M⁺ + 1); ¹H NMR (CD₃OD) δ 1.44 (3H, t, J = 7.8 Hz, CH₃CH₂S), 2.44–2.51 (1H, m, CH₂–2'), 2.90–2.98 (1H, m, CH₂–2'), 3.24 (2H, q, J = 6.86 Hz, CH₃CH₂S), 3.77–3.91 (2H, m, CH₂–5'), 4.09 (1H, bs, H-4'), 4.62–4.64 (1H, m, H-3'), 6.46 (t, J = 7.0 Hz, H-1'), 8.18 (1H, s, H-8).

2-(Propylthio)-2'-deoxyadenosine (53).

To a suspension of potassium *tert*-butoxide (112 mg, 1 mmol) in dry DMF (2 mL) in a sealed tube was added propanethiol (75 mg, 89 μ L, 1 mmol), and the reaction mixture was stirred at room temperature for 30 min. A solution of 2-chloro-2'-deoxy-*N*⁶-methyladenosine (**37**; 31 mg, 0.1 mmol) in dry DMF (1 mL) was added to the above mixture, and the reaction was stirred and heated at 110 °C for 4 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to afford **53** as a colorless solid (25 mg, 0.08 mmol, 76% yield): MS (CI-NH₃) 326 (M⁺ + 1); ¹H NMR (CD₃OD) δ 1.12 (3H, t, J = 7.8 Hz, CH₃CH₂CH₂S), 1.76–1.84 (2H, m, CH₃CH₂CH₂S), 2.45–2.51 (1H, m, CH₂–2'), 2.88–2.94 (1H, m, CH₂–2'), 3.03 (2H, bs, 2OH), 3.18 (2H, q, J = 5.9 Hz, CH₃CH₂CH₂S), 3.78–3.90 (2H, m, CH₂–5'), 4.08–4.11 (1H, m, H-4'), 4.62–4.65 (1H, m, H-3'), 6.43 (1H, t, J = 6.8 Hz, H-1'), 8.03 (2H, bs, NH₂), 8.22 (1H, s, H-8).

8-Bromo-2'-deoxyadenosine (55).

A mixture of 2'-deoxyadenosine (**54**; 270 mg, 1 mmol) and *N*-bromosuccinimide (267 mg, 1.5 mmol) in dry DMF (6 mL) was stirred at room temperature for 12 h under nitrogen

atmosphere. The solvent was removed under reduced pressure, and the residue was purified using pTLC (CHCl₃/MeOH, 9/1) to give **55** as a colorless solid (132 mg, 0.40 mmol, 40% yield): MS (CI-NH₃) 330 (M⁺+ 1); ¹H NMR (CD₃OD) δ 2.18–2.22 (1H, m, CH₂-2'), 3.23–3.30 (1H, m, CH₂-2'), 3.48–3.54 (1H, m, CH₂-5'), 3.66–3.70 (1H, m, CH₂-5'), 3.92 (1H, bs, H-4'), 4.52 (1H, bs, H-3'), 5.31–5.38 (2H, bs, 2 OH), 6.32 (1H, t, *J* = 6.9 Hz, H-1'), 7.55 (2H, bs, NH₂), 8.14 (1H, s, H-2).

8-Methoxy-2'-deoxyadenosine (**56**).

To a solution of 8-bromo-2'-deoxyadenosine (**55**; 50 mg, 0.15 mmol) in dry DMF (2 mL) was added sodium methoxide (54 mg, 1 mmol), and the reaction mixture was stirred and heated in a sealed tube at 110 °C for 6 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to give **56** as a light-yellow solid (30 mg, 0.11 mmol, 72% yield): MS (CI-NH₃) 282 (M⁺+ 1); ¹H NMR (CD₃OD) δ 2.20–2.27 (1H, m, CH₂-2'), 2.48–2.62 (1H, m, CH₂-2'), 3.66 (3H, s, OCH₃), 3.71–3.90 (2H, m, CH₂-5'), 4.09 (1H, bs, H-4'), 4.60 (1H, bs, H-3'), 6.34 (1H, t, *J* = 6.0 Hz, H-1'), 8.06 (1H, s, H-2).

8-(Methylthio)-2'-deoxyadenosine (**57**).

To a solution of 8-bromo-2'-deoxyadenosine (**55**, 50 mg, 0.15 mmol) in dry DMF (2 mL) was added sodium thiomethoxide (70 mg, 1 mmol), and the reaction mixture was stirred and heated in a sealed tube at 110 °C for 4 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to give the desired compound 8-(methylthio)-2'-deoxyadenosine (**57**) as a light-yellow solid (37.8 mg, 0.13 mmol, 85% yield): MS (EI) 297 (M⁺); ¹H NMR (CD₃OD) δ 2.20–2.28 (m, 1H, CH₂-2'), 2.47–2.61 (1H, m, CH₂-2'), 2.76 (3H, s, SCH₃), 3.68–3.91 (2H, m, CH₂-5'), 4.01 (1H, bs, H-4'), 4.60 (1H, m, H-3'), 6.36 (1H, t, *J* = 5.9 Hz, H-1'), 8.10 (1H, s, H-8).

8-(Methylamino)-2'-deoxyadenosine (**58**).

A 40% aqueous solution of methylamine (5 mL) was added to 8-bromo-2'-deoxyadenosine (**55**, 50 mg, 0.15 mmol), and the reaction mixture was stirred at room temperature for 3 h. The solvent was removed under nitrogen flow, and the residue was purified using pTLC (CHCl₃/MeOH, 9/1) to afford **58** as a white solid (37.8 mg, 0.14 mmol, 90% yield): MS (CI-NH₃) 281 (M⁺+ 1); ¹H NMR (CD₃OD) δ 2.11–2.52 (2H, m, CH₂-2'), 3.31 (3H, s, NCH₃), 3.81–3.84 (2H, m, CH₂-5'), 4.06 (1H, m, H-4'), 4.58 (1H, m, H-3'), 6.44 (1H, t, *J* = 5.8 Hz, H-1'), 7.99 (1H, s, H-8).

2'-Deoxy-*N*⁶-methoxyladenosine (**59**).

To a mixture of 6-chloro-2'-deoxypurine riboside (25 mg, 0.092 mmol) and methoxyamine hydrochloride (100 mg, 1.19 mmol) in DMF (2 mL) was added 1 M NaOH (1.19 mL). The reaction mixture was stirred at room temperature for 72 h and then neutralized with 0.1 M HCl. The mixture was evaporated to dryness and chromatographed by pTLC (CHCl₃/MeOH, 90/10) to obtain the desired compound **59** (14 mg, 0.050 mmol, 54% yield): MS (CI-NH₃) 282 (M⁺+ 1), 299 (M + NH₄⁺); ¹H NMR (CD₃OD) δ 2.52–2.58 (1H, m, CH₂-2'),

2.74–2.83 (1H, m, CH₂-2'), 3.80 (2H, m, CH₂-5'), 3.85 (3H, s, OCH₃), 4.14 (1H, bs, H-4'), 4.61 (1H, m, H-3'), 6.39 (1H, t, *J* = 6.9 Hz, H-1'), 7.93 (1H, s, H-2), 8.14 (1H, s, H-8).

Carbocyclic 2-Amino-*N*⁶-methyl-2'-deoxyadenosine (**61**).

A solution of carbocyclic 2-amino-6-chloro-2'-deoxyadenosine (**60**; 28 mg, 0.1 mmol) and 40% aqueous methylamine (4 mL) was stirred at room temperature for 3 h. The solvent was removed under reduced pressure, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 9/1) to provide **61** as colorless solid (26 mg, 0.09 mmol, 92% yield): MS (CI-NH₃) 279 (*M*⁺ + 1); ¹H NMR (CD₃OD) δ 1.72–1.79 (1H, m, CH₂-2'), 2.01–2.19 (2H, m, CH₂-6'), 2.20–2.29 (1H, m, CH₂-2'), 2.32–2.43 (1H, m, H-1'), 2.96 (3H, s, N-CH₃), 3.58–3.69 (2H, m, CH₂-5'), 4.20 (1H, bs, H-3'), 7.75 (1H, s, H-8).

2'-Deoxy-4'-thioadenosine *S*-Oxide (**63**).

A solution of sodium metaperiodate (22.5 mg, 0.105 mmol) in water (0.4 mL) was added dropwise to a vigorously stirred ice-cold solution of 2'-deoxy-4'-thioadenosine (**62**; 13.3 mg, 0.050 mmol) in methanol (1 mL). The reaction mixture was stirred for 48 h at room temperature. The solvent was removed under nitrogen purging, and the residue was chromatographed using pTLC (CHCl₃/MeOH, 10/1) to obtain the desired 2'-deoxy-4'-thioadenosine *S*-oxide, **63** (mixture of diastereomers), as a colorless solid (14.0 mg, 0.049 mmol, 98% yield): MS (CI-NH₃) 284 (*M*⁺ + 1); ¹H NMR (CD₃OD) δ 2.70–3.19 (2H, m, CH₂-2'), 3.44–3.48 (1H, m, H-4'), 4.01–4.07 (2H, m, CH₂-5'), 4.55–4.66 (1H, 2m, H-3'), 6.08–6.28 (1H, 2m, H-1'), 8.20, 8.25 (1H, 2s, H-2), 8.26, 8.29 (1H, 2s, H-8).

2'-Deoxy-5'-[diethyl(*O*-phosphorylmethyl)]adenosine (**64**).

A flame-dried 50-mL round-bottom flask was charged with 2'-deoxyadenosine (**51**; 270 mg, 1 mmol) and potassium *tert*-butoxide (146 mg, 1.3 mmol) in dry DMF (5 mL) under argon atmosphere, and the reaction mixture was stirred at room temperature for 2 h. A solution of diethyl tosylmethanephosphonate (320 mg, 1.1 mmol) in dry DMF (1 mL) was added dropwise, and the reaction mixture was allowed to stir for 3 days at room temperature. The solvent was removed by nitrogen purging, and the crude product was purified by pTLC (CHCl₃/MeOH, 85/15) to afford **64** as a light-yellow solid (128 mg, 0.32 mmol, 32% yield): MS (CI-NH₃) 402 (*M*⁺ + 1); ¹H NMR (CD₃OD) δ 1.21–1.25 (6H, m, OCH₂CH₃); 2.34–2.42 (1H, m, CH₂-2'), 2.74–2.85 (1H, m, CH₂-2'), 3.44 (2H, d, *J* = 10.5 Hz, -CH₂-P), 3.71–4.13 (6H, m, CH₂-5' and P-CH₂CH₃), 4.19 (1H, m, H-4'), 4.60 (1H, m, H-3'), 6.42 (1H, t, *J* = 6.5 Hz, H-1'), 7.97 (2H, bs, NH₂), 8.18 (1H, s, H-2), 8.26 (1H, s, H-8).

Pharmacological Analyses.

P2Y₁ receptor-promoted stimulation of inositol phosphate formation by adenine nucleotide analogues was measured in turkey erythrocyte membranes as previously described.^{10,39} The EC₅₀ values were averaged from 3–8 independently determined concentration-effect curves for each compound. Briefly, 1 mL of washed turkey erythrocytes was incubated in inositol-free medium (DMEM; Gibco, Gaithersburg, MD) with 0.5 mCi of 2-[³H]myo-inositol (20 Ci/mmol; American Radiolabeled Chemicals, Inc., St. Louis, MO) for 18–24 h in a humidified atmosphere of 95% air/5% CO₂ at 37 °C. Erythrocyte ghosts were prepared by

rapid lysis in hypotonic buffer (5 mM sodium phosphate, pH 7.4, 5 mM MgCl₂, 1 mM EGTA) as described.³⁹ Phospholipase C activity was measured in 25 μ L of [³H]inositol-labeled ghosts (approximately 175 μ g of protein, 200–500 000 cpm/assay) in a medium containing 424 μ M CaCl₂, 0.91 mM MgSO₄, 2 mM EGTA, 115 mM KCl, 5 mM KH₂PO₄, and 10 mM Hepes, pH 7.0. Assays (200 μ L final volume) contained 1 μ M GTP γ S and the indicated concentrations of nucleotide analogues. Ghosts were incubated at 30 °C for 5 min, and total [³H]inositol phosphates were quantitated by anion-exchange chromatography as previously described.^{10,39} Stimulation of inositol phosphate formation in 1321N1 human astrocytoma cells stably expressing recombinant human P2Y₂ receptors (activated by 100 nM UTP), recombinant human P2Y₄ receptors (activated by 100 nM UTP), and recombinant rat P2Y₆ receptors (activated by 100 nM UDP) was measured in a similar fashion.^{21,38}

Data Analysis.

Agonist potencies were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC₅₀ values (mean $\pm$ standard error) represent the concentration at which 50% of the maximal effect is achieved. Relative efficacies (%) were determined by comparison with the effect produced by a maximal effective concentration of 2-MeSADP in the same experiment.

Antagonist IC₅₀ values (mean $\pm$ standard error) represent the concentration needed to inhibit by 50% the effect elicited by 10 nM 2-MeSADP. The percent of maximal inhibition is equal to 100 minus the residual fraction of stimulation at the highest antagonist concentration.

All concentration-effect curves were repeated in at least three separate experiments carried out with different membrane preparations using duplicate or triplicate assays.

Acknowledgment.

We thank Gilead Sciences (Foster City, CA) for financial support to E.N. and Dr. Stefano Moro (NIDDK) for helpful discussions. We also are grateful to Dr. Lewis Pannell, Noel Whittaker, Mary Furr, and Wesley White for technical assistance. This work was supported by USPHS Grants GM38213 and HL54889.

Abbreviations:

ATP	adenosine 5'-triphosphate
DEAE	diethylaminoethyl
DMF	dimethylformamide
DMSO	dimethyl sulfoxide
FAB	fast atom bombardment (mass spectroscopy)
HPLC	high-pressure liquid chromatography
MS	mass spectroscopy
HRMS	high-resolution mass spectroscopy

IAN	isoamyl nitrite
2-MeSADP	2-(methylthio)adenosine 5'-diphosphate
NBS	<i>N</i> -bromosuccinimide
NNDA	<i>N,N</i> -dimethylaniline
Py	pyridine
TBAP	tetrabutylammonium phosphate
TEAA	triethylammonium acetate
pTLC	preparative thinlayer chromatography

References

- (1). Fredholm BB; Abbracchio MP; Burnstock G; Dubyak GR; Harden TK; Jacobson KA; Schwabe U; Williams M Toward a revised nomenclature for P1 and P2 receptors. *Trends Pharm. Sci* 1997, 18, 79–82. [PubMed: 9133776]
- (2). North RA; Barnard EA Nucleotide receptors. *Curr. Opin. NeuroBiol* 1997, 7, 346–357. [PubMed: 9232809]
- (3). Webb TE; Simon J; Krishek BJ; Bateson AN; Smart TG; King BF; Burnstock G; Barnard EA Cloning and functional expression of a brain G-protein-coupled ATP receptor. *FEBS Lett.* 1993, 324, 219–225. [PubMed: 8508924]
- (4). Schachter JB; Li Q; Boyer JL; Nicholas RA; Harden TK 2nd messenger cascade specificity and pharmacological selectivity of the human P2Y₁-purinoceptor. *Br. J. Pharmacol.* 1996, 118, 167–173. [PubMed: 8733591]
- (5). Janssens R; Communi D; Pirotton S; Samson M; Parmentier M; Boeynaems J-M Cloning and tissue distribution of the human P2Y₁ receptor. *Biochem. Biophys. Res. Commun.* 1996, 221, 588–593. [PubMed: 8630005]
- (6). Ayyanathan K; Webb TE; Sandhu AK; Athwal RS; Barnard EA; Kunapuli SP Cloning and chromosomal localization of the human P2Y₁ purinoceptor. *Biochem. Biophys. Res. Commun.* 1996, 218, 783–788. [PubMed: 8579591]
- (7). Burnstock G; King BF Numbering of cloned P2 purinoceptors. *Drug Dev. Res.* 1996, 38, 67–71.
- (8). Communi D; Govaerts C; Parmentier M; Boeynaems JM Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. *J. Biol. Chem.* 1997, 272, 31969–31973. [PubMed: 9405388]
- (9). Lazarowski ER; Homolya L; Boucher RC; Harden TK Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. *J. Biol. Chem.* 1997, 272, 24348–24354. [PubMed: 9305892]
- (10). Harden TK; Hawkins PT; Stephens L; Boyer JL; Downes P Phosphoinositide hydrolysis by guanosine 5'-(gamma-thio)triphosphate-activated phospholipase C of turkey erythrocyte membranes. *Biochem. J.* 1988, 252, 583–593. [PubMed: 2843174]
- (11). Jin J; Daniel JL; Kunapuli SP Molecular basis for ADP-induced platelet activation. II. The P2Y₁ receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. *J. Biol. Chem.* 1998, 273, 2030–2034. [PubMed: 9442040]
- (12). Hechler B; Leon C; Vial C; Vigne P; Frelin C; Cazenave JP; Gachet C The P2Y₁ receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. *Blood* 1998, 92, 152–159. [PubMed: 9639511]
- (13). Crowley MR Oxygen-induced pulmonary vasodilation is mediated by adenosine triphosphate in newborn lambs. *J. Cardiovasc. Pharmacol.* 1997, 30, 102–109. [PubMed: 9268228]

- (14). Loubatières-Mariani M-M; Hillaire-Buys D; Chapal J; Bertrand G; Petit P P2 purinoceptor agonists: New insulin secretagogues potentially useful in the treatment of noninsulin-dependent diabetes mellitus In *Purinergic Approaches in Experimental Therapeutics*; Jacobson KA, Jarvis MF, Eds.; Wiley: New York, 1997; pp 253–260.
- (15). Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P P2Y₁-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. *Br. J. Pharmacol.* 1998, 124, 157–164. [PubMed: 9630355]
- (16). Virginio C; Robertson G; Surprenant A; North RA Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X₁, P2X₃, and heteromeric P2X_{2/3} receptors. *Mol. Pharmacol.* 1998, 53, 969–973. [PubMed: 9614197]
- (17). Humphreys BD; Virginio C; Surprenant A; Rice J; Dubyak GR Isoquinolines as antagonists of the P2X₇ nucleotide receptor: high selectivity for the human versus rat receptor homologues. *Mol. Pharmacol.* 1998, 54, 22–32. [PubMed: 9658186]
- (18). Kim Y-C; Camaioni E; Ziganshin AU; Ji X-J; King BF; Wildman SS; Rychkov A; Yoburn J; Kim H; Mohanram A; Harden TK; Boyer JL; Burnstock G; Jacobson KA Synthesis and structure activity relationships of pyridoxal-6-azoaryl-5'-phosphate and phosphonate derivatives as P2 receptor antagonists. *Drug Dev. Res.* in press.
- (19). Boyer JL; Romero-Avila T; Schachter JB; Harden TK Identification of competitive antagonists of the P2Y₁ receptor. *Mol. Pharmacol.* 1996, 50, 1323–1329. [PubMed: 8913364]
- (20). Camaioni E; Boyer JL; Mohanram A; Harden TK; Jacobson KA Deoxyadenosine-bisphosphate derivatives as potent antagonists at P2Y₁ receptors. *J. Med. Chem.* 1998, 41, 183–190. [PubMed: 9457242]
- (21). Boyer JL; Mohanram A; Camaioni E; Jacobson KA; Harden TK Competitive and selective antagonism of P2Y₁ receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. *Brit. J. Pharmacol.* 1998, 124, 1–3. [PubMed: 9630335]
- (22). Boyer JL; Lazarowski E; Chen X-H; Harden TK Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase but does not activate phospholipase C. *J. Pharmacol. Exp. Ther.* 1993, 267, 1140–1146. [PubMed: 8263774]
- (23). Boyer JL; Mohanram A; Delaney S; Waldo G; Harden TK Signaling mechanism and pharmacological selectivity of an avian P2 receptor Nucleotides and their receptors in the nervous system; Leipzig, Germany, Aug 1, 1998; Abstract A03.
- (24). Cristalli G; Vittori S; Eleuteri A; Volpini R; Camaioni E; Lupidi G Synthesis of 2'-deoxynucleoside derivatives of 1-deazapurine. *Nucleosides Nucleotides* 1994, 13, 835–848.
- (25). Verheggen I; van Aerschot A; Toppet S; Snoeck R; Janssen G; Balzarini J; de Clercq E; Herdewijn P Synthesis and antiherpes virus activity of 1,5-anhydrohexitol nucleosides. *J. Med. Chem.* 1993, 36, 2033–2040. [PubMed: 8393114]
- (26). Messini L; Tiwari KN; Montgomery JA; Secrist JA, III. Synthesis and Biological Activity of 4'-Thio-2'-deoxy Purine Nucleosides; 13th International Round Table on Nucleosides, Nucleotides and their Biological Applications; Sept. 6–10, 1998.
- (27). Shealy YF; O'Dell CA Carbocyclic Analogues of 2'-Deoxyadenosine. *Tetrahedron Lett.* 1969, 2231–2234.
- (28). Robins MJ; Fouron Y; Mengel R Adenosine 2',3'-riboepoxide. Synthesis, intramolecular degradation, and transformation into 3'-substituted xylofuranosyl nucleosides and the lyxoepoxide. *J. Org. Chem.* 1974, 39, 1564–1570. [PubMed: 4833508]
- (29). Robins MJ; Uza'nski B Nucleic acid related compounds. 33. Conversions of adenosine and guanosine to 2,6-dichloro, 2-amino-6-chloro, and derived nucleosides. *Can. J. Chem.* 1981, 59, 2601–2607.
- (30). van Aerschot A; Mamos P; Weyns N; Ikeda S; de Clercq E; Herdewijn P Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents. *J. Med. Chem.* 1993, 36, 2938–2942. [PubMed: 8411010]
- (31). Hoffman DJ; Whistler RL Synthesis and properties of nucleotides containing 4-thio-D-ribofuranoside. *Biochemistry* 1970, 9, 2367–2372. [PubMed: 4316459]
- (32). Hancox EL; Walker RT Some reactions of 4'-thionucleosides and their sulfones. *Nucleosides Nucleotides* 1996, 15, 1–3.

- (33). Fischer B; Boyer JL; Hoyle CHV; Ziganshin AU; Brizzolara AL; Knight GE; Zimmet J; Burnstock G; Harden TK; Jacobson KA Identification of potent, selective P2Y-purinoceptor agonists - structure-activity-relationships for 2-thioether derivatives of adenosine 5'-triphosphate. *J. Med. Chem.* 1993, 36, 3937–3946. [PubMed: 8254622]
- (34). Boyer JL; Siddiqi S; Fischer B; Romero-Avila T; Jacobson KA; Harden TK Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. *Br. J. Pharmacol.* 1996, 118, 1959–1964. [PubMed: 8864529]
- (35). van der Wenden EM; Carnielli M; Roelen HC; Lorenzen A; von Frijtag Drabbe Künzel JK; IJzerman AP 5'-substituted adenosine analogues as new high-affinity partial agonists for the adenosine A₁ receptor. *J. Med. Chem.* 1998, 41, 102–108. [PubMed: 9438026]
- (36). Jasper JR; Insel PA Evolving concepts of partial agonism. The beta-adrenergic receptor as a paradigm. *Biochem. Pharmacol.* 1992, 43, 119–130. [PubMed: 1346741]
- (37). Jacobson KA; Hoffmann C; Kim Y-C; Camaioni E; Nandanan E; Jang SY; Guo D-P; Ji X.-d.; von Kügelgen I; Moro S; Ziganshin AU; Rychkov A; King BF; Brown S; Wildman SS; Burnstock G; Boyer JL; Mohanram A; Harden TK Molecular recognition in P₂ receptors: Ligand development aided by molecular modeling and mutagenesis. *Prog. Brain Res.* in press.
- (38). Jacobson KA; Kim Y-C; Wildman SS; Mohanram A; Harden TK; Boyer JL; King BF; Burnstock G A pyridoxine cyclic-phosphate and its 6-arylazo-derivative selectively potentiate and antagonize activation of P2X₁ receptors. *J. Med. Chem.* 1998, 41, 2201–2206. [PubMed: 9632352]
- (39). Boyer JL; Downes CP; Harden TK Kinetics of activation of phospholipase C by P₂Y purinergic receptor agonists and guanine nucleotides. *J. Biol. Chem.* 1989, 264, 884–890. [PubMed: 2910869]

Figure 1.
Structures of purine and pyrimidine nucleotide analogues. The corresponding ammonium salts were synthesized and tested for biological activity.

Figure 2.

Effects of deoxyadenosine bisphosphate derivatives on phospholipase C in turkey erythrocyte membranes: both concentration-dependent stimulation of inositol phosphate formation by 2-MeSADP (●), compound 9 (□), and compound 36 (○) and its inhibition in the presence of 10 nM 2-MeSADP by compound 6 (▲) and compound 9 (■). Membranes from [³H]-inositol-labeled erythrocytes were incubated for 5 min at 30 °C in the presence of the indicated concentrations of 2-MeSADP or of test compound, either alone or in combination with 10 nM 2-MeSADP. The data shown are typical curves for at least three experiments carried out in duplicate using different membrane preparations.

Figure 3. Effects of 2'-position substitution of adenosine 3',5'-bisphosphate derivatives¹⁷ on agonist versus antagonist properties at turkey erythrocyte P2Y₁ receptors. IC₅₀ and EC₅₀ values are given in μ M.

Scheme 1.

Synthesis of Nucleoside Precursors of 2-Chloro- and 2-Alkylthio-Substituted Analogues of *N*⁶-Methyladenosine 3',5'-Bisphosphate^a

^a (a) Ac₂O, pyridine, 25 °C, 2 h; (b) (1) IAN, CH₂I₂, 85 °C, 1 h, (2) 40% aq MeNH₂, 25 °C, 1 h; (c) RSH, KBu^tO, or CH₃SNa, DMF, 110 °C, 4 h; (d) (1) POCl₃, (MeO)₃PO, Proton Sponge, 0 °C, 1 h, (2) NH₄HCO₃.

Scheme 2.

Synthesis of 2-Iodo-*N*⁶-methyladenosine and Related Nucleosides^a

^a (a) Ac₂O, Py, 65 °C, 4 h; (b) POCl₃, NNDA, TEA Cl, CH₃CN, 90 °C, 10 min; (c) 40% aq MeNH₂, 25 °C, 2 h; (d) Ac₂O, Py, 25 °C, 4 h; (e) (1) POCl₃, (MeO)₃PO, Proton Sponge, 0 °C, 1 h, (2) NH₄HCO₃; (f) IAN, CH₂I₂, 85 °C, 1 h.

Scheme 3.

Synthesis of Nucleoside Precursors of 2-Alkylthio-Substituted Analogues of Adenosine 3', 5'-Bisphosphate^a

^a (a) RSH, KBu^tO, or CH₃SNa, DMF, 110 °C, 4 h; (b) (1) POCl₃, (CH₃O)₃PO, Proton Sponge, 0 °C, 1 h, (2) NH₄HCO₃.

Scheme 4.

Synthesis of Nucleoside Precursors of 8-Substituted Analogues of Adenosine 3',5'-Bisphosphate^a

^a (a) NBS, DMF, 25 °C, 12 h; (b) NaOCH₃, DMF, 110 °C, 6 h, or NaSCH₃, DMF 110 °C, 4 h, or MeNH₂, MeOH, 25 °C, 3 h; (c) (1) POCl₃, (CH₃O)₃PO, Proton Sponge, 0 °C, 1 h, (2) NH₄HCO₃.

Scheme 5.

Synthesis of Precursors of Various Ribose-Modified Analogues (carbocyclic and 4'-thio) of Adenosine 3',5'-Bisphosphate^a

^a (a) 40% aq CH_3NH_2 , 25 °C, 3 h; (b) (1) POCl_3 , $(\text{MeO})_3\text{PO}$, Proton Sponge, 0 °C, 1 h, (2) NH_4HCO_3 ; (c) NaIO_4 , 25 °C, 1 h.

Scheme 6.

Synthesis of a 5'-O-Phosphonylmethyl Analogue of Adenosine 3',5'-Bisphosphate^a

^a (a) $\text{K}^+\text{Bu}^-\text{O}^-$, DMF, 25 °C, 3 days; (b) (1) POCl_3 , $(\text{CH}_3\text{O})_3\text{PO}$, Proton Sponge, 0 °C, 1 h, (2) NH_4HCO_3 .

Scheme 7.

Synthesis of 3',5'-Cyclic Di- and Tetrakisphosphate Derivatives^a

^a (a) (1) Carbonyldiimidazole, DMF, 25 °C, 12 h, (2) bis(tributylammonium)pyrophosphate, 25 °C, 42 h, (3) NH_4HCO_3 .

Table 1.Structures of Deoxyadenosine 3',5'-Bisphosphate Derivatives^a

compd	R	R'	R''	X	Y	Z
1	NH ₂	H	H	N	H	O
2	NH-CH ₃	H	H	N	H	O
3	NH ₂	H	H	N	OH	O
4	NH-CH ₃	H	H	CH	H	O
5	NH ₂	Cl	H	N	H	O
6	NH-CH ₃	Cl	H	N	H	O
7	NH-CH ₃	I	H	N	H	O
8	NH-OCH ₃	H	H	N	H	O
9	NH ₂	S-CH ₃	H	N	H	O
10	NH-CH ₃	S-CH ₃	H	N	H	O
11	NH ₂	S-CH ₂ CH ₃	H	N	H	O
12	NH-CH ₃	S-CH ₂ CH ₃	H	N	H	O
13	NH ₂	S-(CH ₂) ₂ CH ₃	H	N	H	O
14	NH-CH ₃	S-(CH ₂) ₂ CH ₃	H	N	H	O
15	NH-CH ₃	S-CH ₂ CH=CH ₂	H	N	H	O
16	NH-CH ₃	S-(CH ₂) ₅ CH ₃	H	N	H	O
17a	NH-CH ₃	NH ₂	H	N	H	O
17b	OH	NH ₂	H	N	H	O
18	NH ₂	H	CH ₃	N	H	O
19	NH ₂	H	CH=CH ₂	N	H	O
20	NH ₂	H	O-CH ₃	N	H	O
21	NH ₂	H	S-CH ₃	N	H	O
22	NH ₂	H	NH-CH ₃	N	H	O
23	NH ₂	H	H	N	H	S
24	NH ₂	H	H	N	H	CH ₂
25	NHCH ₃	NH ₂	H	N	H	CH ₂

^aThe structures of compounds **26-36** are given in Figure 2.

Table 2.

In Vitro Pharmacological Data for Stimulation of PLC at Turkey Erythrocyte P2Y₁ Receptors (agonist effect) and Inhibition of PLC Stimulation Elicited by 10 nM 2-MeSADP (antagonist effect), for at Least Three Separate Determinations

compd	agonist effect, % of maximal increase ^a	EC ₅₀ , μ M ^a	antagonist effect, % of maximal inhibition ^b	IC ₅₀ , μ M ^b (n)
1	12 $\pm$ 3	6.29 $\pm$ 2.54	87 $\pm$ 4	5.76 $\pm$ 0.68
2 ^e	NE		99 $\pm$ 1	0.331 $\pm$ 0.059 (5)
3	44 $\pm$ 5	2.34 $\pm$ 0.50	56 $\pm$ 6	14.9 $\pm$ 1.0 (4)
4	NE		96 $\pm$ 2	0.904 $\pm$ 0.239
5	19 $\pm$ 3	0.651 $\pm$ 0.160	80 $\pm$ 3	2.01 $\pm$ 0.83
6 ^e	NE		95 $\pm$ 1	0.206 $\pm$ 0.053
7	13 $\pm$ 3 (n = 2)	4.44	87 $\pm$ 3	0.891 $\pm$ 0.233
8	NE		low potency/NE	>100 (4)
9	22 $\pm$ 2	0.550 $\pm$ 0.117	78 $\pm$ 2	1.89 $\pm$ 1.07
10	6 $\pm$ 2	<i>d</i>	94 $\pm$ 2	0.362 $\pm$ 0.119
11	16 $\pm$ 1	1.98 $\pm$ 0.42	84 $\pm$ 1	4.59 $\pm$ 1.61
12	NE		94 $\pm$ 1	0.98 $\pm$ 0.27
13 ^e	53 $\pm$ 7	1.71 $\pm$ 0.78	46 $\pm$ 7	<i>c</i> (4)
14	7 $\pm$ 2	<i>d</i>	94 $\pm$ 3	0.449 $\pm$ 0.190
15	NE		97 $\pm$ 3	0.475 $\pm$ 0.206
16	NE		100	3.37 $\pm$ 0.91
17a	4	<i>d</i>	96 $\pm$ 2	1.85 $\pm$ 0.74
17b	NE		93 $\pm$ 4	14.9 $\pm$ 5.1
18	NE		53 $\pm$ 10	75.1 $\pm$ 14.5
19	NE		59 $\pm$ 10	30.7 $\pm$ 14.8
20	NE		NE	
21	NE		low potency/NE	
22	NE		low potency/NE	(2)
23	56 $\pm$ 7	12.2 $\pm$ 3.9	38	<i>c</i>
24	27 $\pm$ 11	7.21 $\pm$ 4.40	73 $\pm$ 11	2.53 $\pm$ 0.57
25	26 $\pm$ 3	6.49 $\pm$ 2.76	74 $\pm$ 3	5.42 $\pm$ 2.13
26	NE		NE	
27	22 $\pm$ 5	27.7 $\pm$ 16.6	78 $\pm$ 5	19.6 $\pm$ 6.1 (4)
28	NE		NE	
29a	NE		low potency/NE	
29b	14 $\pm$ 2	0.02	87 $\pm$ 4	0.158 $\pm$ 0.064
30	46 $\pm$ 10 at 100 μ M	low-potency agonist	NE	
31	49 $\pm$ 7 at 100 μ M	low-potency agonist	low potency/NE	
32	NE		NE	
33	NE		NE	

compd	agonist effect, % of maximal increase ^a	EC ₅₀ , μ M ^a	antagonist effect, % of maximal inhibition ^b	IC ₅₀ , μ M ^b (n)
34	NE		NE	
35	NE		NE	
36^e	100	2.99 $\pm$ 0.35	NE	(2)

^a Agonist potencies were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC₅₀ values (mean (standard error) represent the concentration at which 50% of the maximal effect is achieved. Relative efficacies (%) were determined by comparison with the effect produced by a maximal effective concentration of 2-MeSADP in the same experiment. Small increase refers to <10% at 100 μ M.

^b Antagonist IC₅₀ values (mean (standard error) represent the concentration needed to inhibit by 50% the effect elicited by 10 nM 2-MeSADP. The percent of maximal inhibition is equal to 100 minus the residual fraction of stimulation at the highest antagonist concentration; *n* = 3, unless otherwise indicated in parentheses.

^c The IC₅₀ of partial agonists with high intrinsic agonist efficacy (>60% of the maximal response) cannot be accurately estimated under these assay conditions due to the small difference between the submaximal response of the full agonist (2-MeSADP) and that produced by the partial agonist.

^d EC₅₀ was not calculated for increases of >10% at 100 μ M.

^e **2**, MRS 2179; **6**, MRS 2216; **13**, MRS 2242; **36**, MRS 2255. NE, no effect at 100 μ M. Chemical structures are given in Table 1 and Figure 1.

Table 3.

Synthetic Data for Nucleotide Derivatives, Including Structural Verification Using HRMS and Purity Verification Using HPLC

compd	formula	FAB (M - H ⁺)		HPLC <i>t</i> _R , min ^a		yields, % ^b
		calcd	found	system A	system B	
1	C ₁₀ H ₁₅ O ₉ N ₅ P ₂	410.0267	410.0249	5.98	11.51	44
2	C ₁₁ H ₁₇ O ₉ N ₅ P ₂	424.0423	424.0404	6.93	12.32	41
3	C ₁₀ H ₁₅ O ₁₀ N ₅ P ₂	426.0216	426.0226	6.12	10.51	15
4	C ₁₂ H ₁₈ O ₉ N ₄ P ₂	423.0471	423.0479	8.49	10.64	19
5	C ₁₀ H ₁₄ O ₉ N ₅ P ₂ Q	443.9877	443.9872	7.20	12.14	58
6	C ₁₀ H ₁₆ O ₉ N ₅ P ₂ Cl	458.0034	458.0035	8.51	11.42	17
7	C ₁₁ H ₁₆ O ₉ N ₅ P ₂ I	549.9390	549.9396	7.84	8.40	16
8	C ₁₁ H ₁₇ O ₁₀ N ₅ P ₂	440.0372	440.0358	6.32	10.13	23
9	C ₁₁ H ₁₇ O ₉ N ₅ P ₂ S	456.0144	456.0122	8.14	12.98	48
10	C ₁₂ H ₁₉ O ₉ N ₅ P ₂ S	470.0301	470.0307	9.99	12.07	17
11	C ₁₂ H ₁₉ O ₉ N ₅ P ₂ S	470.0301	470.0307	8.94	9.84	23
12	C ₁₃ H ₂₁ O ₉ N ₅ P ₂ S	484.0457	484.0453	10.49	11.81	23
13	C ₁₃ H ₂₁ O ₉ N ₅ P ₂ S	484.0457	484.0452	7.77	11.65	21
14	C ₁₄ H ₂₃ O ₉ N ₅ P ₂ S	498.0614	498.0605	9.75	12.40	10
15	C ₁₄ H ₂₁ O ₉ N ₅ P ₂ S	496.0457	496.0445	9.20	12.35	13
16	C ₁₇ H ₂₉ O ₉ N ₅ P ₂ S	540.1083	540.1057	12.87	15.11	25
17a	C ₁₁ H ₁₈ O ₉ N ₆ P ₂	439.0532	439.0535	6.48	7.15	19
17b	C ₁₀ H ₁₅ O ₁₀ N ₅ P ₂	426.0216	426.0216	9.28	9.69	39
18	C ₁₁ H ₁₇ O ₉ N ₅ P ₂	424.0423	424.0412	6.07	8.72	9
19	C ₁₂ H ₁₇ O ₉ N ₅ P ₂	436.0423	436.0429	6.43	9.00	13
20	C ₁₁ H ₁₇ O ₁₀ N ₅ P ₂	440.0372	440.0380	4.14	7.28	17
21	C ₁₁ H ₁₇ O ₉ N ₅ P ₂ S	456.0144	456.0160	6.89	8.23	37
22	C ₁₁ H ₁₈ O ₉ N ₆ P ₂	439.0532	439.0497	6.67	9.20	5
23	C ₁₀ H ₁₅ O ₈ N ₅ P ₂ S	426.0038	426.0051	6.75	8.92	13
24	C ₁₁ H ₁₇ O ₈ N ₅ P ₂	408.0474	408.0474	5.97	7.04	24
25	C ₁₂ H ₂₀ O ₈ N ₆ P ₂	437.0740	437.0759	3.70	5.21	10
26	C ₁₀ H ₁₄ O ₆ N ₅ PS	362.0324	362.0319	2.76	7.63	2
27	C ₁₁ H ₁₇ O ₉ N ₅ P ₂	424.0423	424.0432	7.04	7.37	10
28	C ₁₂ H ₁₉ O ₉ N ₅ P ₂	438.0580	438.0580	3.06	4.48	22
29a	C ₁₁ H ₁₅ O ₈ N ₅ P ₂	406.0318	406.0336	7.60	7.47	20
29b	C ₁₁ H ₁₇ O ₁₄ N ₅ P ₄	565.9644	565.9664	6.91	12.11	5
30	C ₁₀ H ₁₄ O ₉ N ₈ P ₂	451.0281	451.0288	3.70	5.78	13
31	C ₁₀ H ₁₆ O ₁₅ N ₈ P ₄	610.9607	610.9602	3.81	5.99	3
32	C ₉ H ₁₄ O ₁₁ N ₂ P ₂	386.9995	386.9977	4.20	9.85	39

compd	formula	FAB (M - H ⁺)		HPLC <i>t</i> _R , min ^a		yields, % ^b
		calcd	found	system A	system B	
33	C ₁₀ H ₁₆ O ₁₁ N ₂ P ₂	401.0151	401.0160	4.63	9.73	39
34	C ₉ H ₁₃ O ₁₁ N ₂ P ₂ F	404.9889	404.9901	3.66	7.83	27
35	C ₉ H ₁₅ O ₁₀ N ₃ P ₂	386.0154	386.0136	2.10	3.34	36
36	C ₁₁ H ₁₇ O ₉ N ₅ P ₂	424.0423	424.0423	4.31	7.56	1

^aPurity of each derivative was 95%, as determined using HPLC (Hewlett-Packard 1090) with two different mobile phases, using an SMT OD-5–60 RP-C₁₈ column (250 × 4.6 mm; Separation Methods Technologies, Inc., Newark, DE). The flow rate was 1 mL/min, with a typical pressure of 100 bar. System A: linear gradient solvent system, 0.1 M TEAA/CH₃CN from 95/5 to 40/60 in 20 min. System B: linear gradient solvent system, 5 mM TBAP/CH₃CN from 80/20 to 40/60 in 20 min.

^bThe percent yields refer to phosphorylation reactions